



617th Meeting of the Health Services Cost Review Commission

February 14, 2024

(The Commission will begin in public session at 11:30 am for the purpose of, upon motion and approval, adjourning into closed session. The open session will resume at 1:00pm)

CLOSED SESSION

11:30 am

1. Discussion on Planning for Model Progression - Authority General Provisions Article, §3-103 and §3-104
2. Update on Administration of Model - Authority General Provisions Article, §3-103 and §3-104

PUBLIC MEETING

1:00 pm

Informational

1. Review of Minutes from the Public and Closed Meetings on January 10, 2024
2. Presentation (update will be provided)

Specific Matters

3. Docket Status – Cases Closed
 - 2640A University of Maryland Medical Center
 - 2641R UM Upper Chesapeake Behavioral Health Pavilion
4. Docket Status – Cases Open
 - 2642N University of Maryland Medical Center
 - 2643N Brook Lane Hospital
 - 2630R UM Shore Medical Center at Easton
5. University of Maryland Rehabilitation and Orthopaedic Institute (UMROI) Recommendation

Subjects of General Applicability

6. Final Recommendation on Maryland Hospital Acquired Conditions Program (MHAC)
7. Final Recommendation on Multi-Visit Patients (MVPs)

8. Draft Recommendation on Readmission Reduction Incentive Program (RRIP) - RY 2026

9. Policy Update and Discussion

- a. AHEAD Model Update
- b. Model Monitoring
- c. Legislative Update
- d. Workgroup Processes Update
- e. Policy Calendar Update

10. Hearing and Meeting Schedule

IN RE: THE PARTIAL RATE

* **BEFORE THE HEALTH
SERVICES**

APPLICATION OF THE

* **COST REVIEW COMMISSION**

UNIVERSITY OF MARYLAND

* **DOCKET: 2023**

MEDICAL CENTER

* **FOLIO: 2452**

BALTIMORE, MARYLAND

* **PROCEEDING: 2642N**

**Staff Recommendation
February 14, 2024**

Introduction

On December 14, 2023, University of Maryland Medical Center (“UMMC,” or “the Hospital”) submitted a partial-rate application requesting the creation of a new rebundled rate for Ambulance – Rebundled (AMR) services. A rebundled rate is approved by the Commission when a hospital provides certain non-physician services through a third-party contractor off-site. By approving a rebundled rate, the Commission makes it possible for a hospital to bill for the services provided off-site, as required by Medicare. The Hospital requests that the rebundled AMR rate be set at the state-wide median and be effective March 1, 2024.

Staff Evaluation

HSCRC policy is to set the rates for new services at the lower of the statewide median or at a rate based on a hospital’s projections. As this service will be provided by a third-party contractor as a rebundled service, no cost finding is necessary. The state-wide median for AMR services is \$6.24 per RVU.

<u>Service</u>	<u>Service Unit</u>	<u>Unit Rate</u>	<u>Projected Volumes</u>	<u>Approved Revenue</u>
Ambulance Services – Rebundled	RVUs	\$6.24	1	\$6

Recommendation

After reviewing the Hospital’s application, the staff recommends:

1. That a rate of \$6.24 be approved effective March 1, 2024 for AMR services;
2. That no change be made to the Hospital’s Global Budget Revenue for the AMR services.
3. That AMR as a rebundled service is exempt from rate realignment.

IN RE: THE PARTIAL RATE	*	BEFORE THE HEALTH SERVICES
APPLICATION OF	*	COST REVIEW COMMISSION
BROOK LANE	*	DOCKET: 2023
HEALTH SERVICES	*	FOLIO: 2453
HAGERSTOWN, MARYLAND	*	PROCEEDING: 2463N

Staff Recommendation
February 14, 2024

Introduction

On January 11, 2024, Brook Lane Health Services (“the Hospital”) submitted a partial rate application to the Health Services Cost Review Commission requesting to bundle therapy revenue from Individual Therapy (ITH) and Group Therapy (GTH) into the room charge Psychiatric Adult (PAD) and Psychiatric Child and Adolescent (PCD) for Inpatient services and into the daily charge for PsychiatricDay/Night (PDC) to be effective January 1, 2024. These services were previously billed separately.

Staff Evaluation

This request is revenue neutral and will not result in any additional revenue for the Hospital. The consolidation of these therapies will bring the Hospital in line with other Psychiatric Hospitals. Staff evaluated the reasonableness of this request by comparing the rates Brook Lane Hospital requested to the rates of Sheppard Pratt. The table below illustrates the analysis that staff completed, which compares the net revenue at Sheppard Pratt and Brook Lane. The net revenue generated at Brook Lane using their requested rates is lower than the net revenue at Sheppard Pratt, which staff believes to be reasonable.

	a	b	c	d = b/c	e=d*a	f	g	h=f/g	i=h*a
	Brook Lane Budgeted Volume	Sheppard Pratt Rate	Sheppard Pratt MarkUp	Net Reimbursement	Net Revenue	Brook Lane Requested Rate	Brook Lane Markup	Net Reimbursement	Net Revenue
PAD	6248	\$ 1,634	1.1453	\$ 1,426	\$ 8,911,127	\$ 1,363	1.1667	\$ 1,168	\$ 7,300,466
PCD	11459	\$ 1,565	1.1453	\$ 1,366	\$ 15,656,349	\$ 1,392	1.1667	\$ 1,193	\$ 13,675,594
PDC	3699	\$ 328	1.1453	\$ 287	\$ 1,059,944	\$ 580	1.1667	\$ 497	\$ 1,839,983
				Total Net Rev	\$ 25,627,420			Total Net Rev	\$ 22,816,043

The Hospital’s new proposed rates are as follows:

	Budgeted Volumes	Approved Revenue	Recommended Unit Rate
Psychiatric Adult (PAD)	6,248	\$8,517,559	\$1,363.23
Psychiatric Child and Adolescent (PCD)	11,459	\$15,955,211	\$1,392.38
Psychiatric Day/Night (PDC)	3,699	\$2,146,708	\$580.35

Recommendation

After reviewing the Hospital's application, the staff recommends as follows:

1. That the Hospital be allowed to collapse Individual Therapy (ITH) and Group Therapy (GTH) into the Psychiatric Adult (PAD) and Psychiatric Child and Adolescent (PCD), and Psychiatric Day/Night (PDC) rate centers;
2. That rates outlined for Psychiatric Adult (PAD) and Psychiatric Child and Adolescent (PCD), and Psychiatric Day/Night (PDC) be approved effective January 1, 2024; and
3. That the rates approved herein be revenue neutral.



maryland
health services
cost review commission

Final Recommendation for the Maryland Hospital Acquired Conditions Program for Rate Year 2026

February 14, 2024

This document contains staff final recommendations for the RY 2026 Maryland Hospital Acquired Conditions Program.

Table of Contents

List of Abbreviations	2
Key Methodology Concepts and Definitions	3
Recommendations	5
Introduction	6
Background	7
Exemption from Federal Hospital-Acquired Condition Programs	7
Overview of the MHAC Policy	8
MHAC Methodology	8
Assessment	9
Statewide PPC Performance Trends	10
Complications Included in Payment Program	10
Monitored Complications	13
Calculating PPC Performance Standards	15
Small Hospital Criteria	16
PPC Clinical Concerns	17
Hospital Scores and Revenue Adjustments	18
Health Equity	20
Stakeholder Feedback and Responses	20
Recommendations	20
Appendix I. Background on Federal Complication Programs	22
Appendix II: RY 2025 MHAC Program Methodology	24
RY 2025 Update: Small Hospital Methodology	28
Appendix III: Monitoring PPCs	30
Appendix IV: Calculating Performance Standards	32
Appendix V: Disparities in PPCs	34

List of Abbreviations

AHRQ	Agency for Health Care Research and Quality
APR-DRG	All Patients Refined Diagnosis Related Groups
CMS	Centers for Medicare & Medicaid Services
CY	Calendar Year
DRG	Diagnosis-Related Group
FFY	Federal Fiscal Year
FY	State Fiscal Year
HAC	Hospital-Acquired Condition
HAI	Hospital Associated Infection
HSCRC	Health Services Cost Review Commission
ICD	International Statistical Classification of Diseases and Related Health Problems
MHAC	Maryland Hospital-Acquired Condition
NHSN	National Healthcare Safety Network
NQF	National Quality Forum
PMWG	Performance Measurement Work Group
POA	Present on Admission
PPC	Potentially Preventable Complication
PSI	Patient Safety Indicator
QBR	Quality-Based Reimbursement
RY	Rate Year
SIR	Standardized Infection Ratio
SOI	Severity of Illness
TCOC	Total Cost of Care
VBP	Value-Based Purchasing
YTD	Year to Date

Key Methodology Concepts and Definitions

Potentially preventable complications (PPCs): 3M originally developed 65 PPC measures, which are defined as harmful events that develop after the patient is admitted to the hospital and may result from processes of care and treatment rather than from the natural progression of the underlying illness. PPCs, like national claims-based hospital-acquired condition measures, rely on **present-on-admission codes** to identify these post-admission complications.

At-risk discharge: Discharge that is eligible for a PPC based on the measure specifications

Diagnosis-Related Group (DRG): A system to classify hospital cases into categories that are similar clinically and in expected resource use. DRGs are based on a patient's primary diagnosis and the presence of other conditions.

All Patients Refined Diagnosis Related Groups (APR-DRG): Specific type of DRG assigned using 3M software that groups all diagnosis and procedure codes into one of 328 All-Patient Refined-Diagnosis Related Groups.

Severity of Illness (SOI): 4-level classification of minor, moderate, major, and extreme that can be used with APR-DRGs to assess the acuity of a discharge.

APR-DRG SOI: Combination of Diagnosis Related Groups with Severity of Illness levels, such that each admission can be classified into an APR-DRG SOI "cell" along with other admissions that have the same Diagnosis Related Group and Severity of Illness level.

Case-Mix Adjustment: Statewide rate for each PPC (i.e., normative value or "norm") is calculated for each diagnosis and severity level. These **statewide norms** are applied to each hospital's case-mix to determine the expected number of PPCs, a process known as **indirect standardization**.

Observed/Expected Ratio: PPC rates are calculated by dividing the observed number of PPCs by the expected number of PPCs. Expected PPCs are determined through case-mix adjustment.

Diagnostic Group-PPC Pairings: Complications are measured at the diagnosis and Severity of Illness level, of which there are approximately 1,200 combinations before one accounts for clinical logic and PPC variation.

Zero norms: Instances where no PPCs are expected because none were observed in the base period at the Diagnosis Related Group and Severity of Illness level.

Policy Overview

Policy Objective	Policy Solution	Effect on Hospitals	Effect on Payers/Consumers	Effects on Health Equity
<p>The quality programs operated by the Health Services Cost Review Commission, including the Maryland Hospital Acquired Conditions (MHAC) program, are intended to ensure that any incentives to constrain hospital expenditures under the Total Cost of Care Model do not result in declining quality of care. Thus, HSCRC's quality programs reward quality improvements and achievements that reinforce the incentives of the Total Cost of Care Model, while guarding against unintended consequences and penalizing poor performance.</p>	<p>The MHAC program is one of several pay-for-performance quality initiatives that provide incentives for hospitals to improve and maintain high-quality patient care and value over time.</p>	<p>The MHAC policy currently holds 2 percent of inpatient hospital revenue at-risk for complications that may occur during a hospital stay as a result of treatment rather than the underlying progression of disease. Examples of the types of hospital acquired conditions included in the current payment program are respiratory failure, pulmonary embolisms, and surgical-site infections.</p>	<p>This policy affects a hospital's overall GBR and so affects the rates paid by payers at that particular hospital. The HSCRC quality programs are all-payer in nature and so improve quality for all patients that receive care at the hospital.</p>	<p>Historically the MHAC policy included the better of improvement and attainment, which incentivized hospitals to improve poor clinical outcomes that are often emblematic of disparities. The protection of improvement has since been phased out to ensure that poor clinical outcomes and the associated health disparities are not made permanent, which is especially important for a measure that is limited to in-hospital complications. In the future, the MHAC policy may provide direct hospital incentives for reducing disparities, similar to the approved readmission disparity gap improvement policy. Also for future consideration is inclusion of electronic Clinical Quality Measures to address areas such as maternal complications, which disproportionately impact lower income, minority patients.</p>

Recommendations

The MHAC policy was redesigned in Rate Year (RY) 2021 to modernize the program for the new Total Cost of Care Model. This RY 2026 final recommendation, in general, maintains the measures and methodology that were developed and approved for RYs 2022 through 2025.¹

These are the final recommendations for the RY 2026 Maryland Hospital Acquired Conditions (MHAC) program:

1. Continue to use 3M Potentially Preventable Complications (PPCs) to assess hospital acquired complications.
 - a. Maintain a focused list of PPCs in the payment program that are clinically recommended and that generally have higher statewide rates and variation across hospitals.
 - b. Assess monitoring PPCs based on clinical recommendations, statistical characteristics, and recent trends to prioritize those for future consideration for updating the measures in the payment program.
 - c. Engage hospitals on specific PPC increases as indicated/appropriate to understand trends and discuss potential quality concerns.
2. Use more than one year of performance data for small hospitals (i.e., less than 21,500 at-risk discharges and/or 22 expected PPCs). The performance period for small hospitals will be CYs 2023 and 2024.
3. Continue to assess hospital performance on attainment only, with adjustment to performance standards for increased stability.
4. Continue to weight the PPCs in the payment program by 3M cost weights as a proxy for patient harm.
5. Maintain a prospective revenue adjustment scale with a maximum penalty at 2 percent and maximum reward at 2 percent and continuous linear scaling with a hold harmless zone between 60 and 70 percent.
6. Future Considerations:
 1. Assess options for streamlining (or simplifying) the quality programs overall, or for the hospital acquired complication measures that are currently included in both the QBR Safety Domain and the MHAC program.
 2. Assess digitally specified quality measures such as electronic Clinical Quality Measures (eCQMs) for future inclusion in quality programs.

¹ See the [RY 2021 policy](#) for detailed discussion of the MHAC redesign, rationale for decisions, and approved recommendations.

Introduction

Maryland hospitals are funded under a population-based revenue system with a fixed annual revenue cap set by the Maryland Health Services Cost Review Commission (HSCRC or Commission) under the All-Payer Model agreement with the Centers for Medicare & Medicaid Services (CMS) beginning in 2014, and continuing under the current Total Cost of Care (TCOC) Model agreement, which took effect in 2019. Under the global budget system, hospitals are incentivized to shift services to the most appropriate care setting and simultaneously have revenue at risk in Maryland's unique, all-payer, pay-for-performance quality programs; this allows hospitals to keep any savings they earn via better patient experiences, reduced hospital-acquired infections, or other improvements in care. Maryland systematically revises its quality and value-based payment programs to better achieve the state's overarching goals: more efficient, higher quality care, and improved population health. It is important that the Commission ensure that any incentives to constrain hospital expenditures do not result in declining quality of care. Thus, the Commission's quality programs reward quality improvements and achievements that reinforce the incentives of the global budget system, while guarding against unintended consequences and penalizing poor performance.

The Maryland Hospital Acquired Conditions (MHAC) program is one of several quality pay-for-performance initiatives that provide incentives for hospitals to improve and maintain high-quality patient care and value over time. The program currently holds 2 percent of hospital revenue at-risk for hospital acquired complications that may occur during a hospital stay as a result of treatment rather than the underlying progression of disease. Examples of the types of hospital acquired conditions included in the current payment program are respiratory failure, pulmonary embolisms, and surgical-site infections.

For MHAC, as well as the other State hospital quality programs, annual updates are vetted with stakeholders and approved by the Commission to ensure the programs remain aggressive and progressive with results that meet or surpass those of the national CMS analogous programs (from which Maryland must receive annual exemptions). For purposes of the RY 2026 MHAC final Policy, staff vetted the updated proposed recommendations in December with the Performance Measurement Workgroup (PMWG), the standing advisory group that meets monthly to discuss Quality policies.

Additionally, with the onset of the Total Cost of Care Model Agreement, each program was overhauled to ensure they support the goals of the Model. For the MHAC policy, the overhaul was completed during

2018, which entailed an extensive stakeholder engagement effort. The major accomplishments of the MHAC program redesign were focusing the payment incentives on a narrower list of clinically significant complications, moving to an attainment only system given Maryland's sustained improvement on complications, adjusting the scoring methodology to better differentiate hospital performance, and weighting complications by their associated cost weights as a proxy for patient harm. The redesign also assessed how hospital performance is converted to revenue adjustments, and ultimately recommended maintaining the use of a linear revenue adjustment scale with a hold harmless zone.

Following the MHAC program redesign, this RY 2026 MHAC policy final proposes minimal changes to the program. The assessment section also includes an evaluation of PPCs in "Monitoring" status consistent with the approved recommendations for RY 2021 going forward, which includes identifying PPCs that should be considered for inclusion back into the MHAC payment program due to worsening performance. Based on this analysis and consideration of stakeholder input, the RY 2026 final recommendation does not propose to move any complications from monitoring to payment.

Background

Exemption from Federal Hospital-Acquired Condition Programs

The Federal Government operates two hospital complications payment programs, the Deficit Reduction Act Hospital Acquired Condition program (DRA-HAC), which reduces reimbursement for hospitalizations with inpatient complications, and the HAC Reduction Program (HACRP), which penalizes hospitals with the highest rates of complications. Detailed information, including HACRP complication measures, may be found in Appendix I. Also, it should be noted that the CMS Value-Based Purchasing program and the analogous Quality Based Reimbursement program contain a safety domain that assess hospital acquired complication measures.

Because of the State's unique all-payer hospital model and its global budget system, Maryland does not directly participate in the federal pay-for-performance programs. Instead, the State administers the Maryland Hospital Acquired Conditions (MHAC) program, which relies on quality indicators validated for use with an all-payer inpatient population. However, the State must submit an annual report to CMS demonstrating that Maryland's MHAC program targets and results continue to be aggressive and progressive, i.e., that Maryland's performance meets or surpasses that of the nation. Specifically, the State must ensure that the improvements in complication rates observed under the All-Payer Model through 2018

are maintained throughout the TCOC model. Based on performance to date, CMS has granted Maryland exemptions from the federal pay-for-performance programs (including the HAC Reduction Program) each year through FFY 2024.

Overview of the MHAC Policy

The MHAC program, which was first implemented for RY 2011, is based on a system developed by 3M Health Information Systems (3M) to identify potentially preventable complications (PPCs) using the present-on-admission variable for eligible secondary diagnosis codes available in claims data. 3M originally developed specifications for 65 PPCs,² which are defined as harmful events that develop after the patient is admitted to the hospital and may result from processes of care and treatment rather than from the natural progression of the underlying illness. For example, the program holds hospitals accountable for venous thrombosis and sepsis that occur during inpatient stays. These complications can lead to 1) poor patient outcomes, including longer hospital stays, permanent harm, and death; and 2) increased costs. Thus, the MHAC program is designed to provide incentives to improve patient care by adjusting hospital budgets based on PPC performance.

MHAC Methodology

Figure 1 provides an overview of the three steps in the RY 2025 MHAC methodology (also see Appendix II) that converts hospital performance to standardized scores, and then payment adjustments, as outlined below:


Step 1. For the PPCs identified for payment, clinically-determined global and PPC-specific exclusions, as well as volume based hospital-level exclusions are identified to ensure fairness in assignment of complications.

Step 2. Case-mix adjustment is used to calculate observed to expected ratios that are then converted to a standardized point based score (0-100 points) based on each hospital's attainment levels using a similar scoring methodology that is used for CMS Value-Based Purchasing and Maryland QBR program.

² In RY 2020, there were 45 PPCs or PPC combinations included in the program, from an initial 65 PPCs in the software, as 3M had discontinued some PPCs and others were deemed not suitable for a pay-for-performance program.

Step 3. Overall hospital scores are then calculated by taking the points for each PPC and multiplying by the 3M PPC cost weights, then summing numerator (points scored) and denominator (possible points) across the PPCs to calculate a percent score. A linear point scale set prospectively is then used to calculate the revenue adjustment percent. This prospective scaling approach differs from national programs that relatively rank hospitals after the performance period. Additionally, the HACRP differs in that it provides no opportunity for rewards and reduces payments by 1 percent for hospitals in the worst-performing quartile.

Figure 1. Overview Rate Year 2025 MHAC Methodology



Assessment

In order to develop the RY 2026 MHAC policy, staff solicited input from the PMWG and other stakeholders. In general, stakeholders support the staff's recommendation to not make major changes to the RY 2026 MHAC program. This section of the report provides an overview of the statewide PPC trends—for those used for payment, under monitoring, and overall—and updates related to 3M clinical logic and MHAC methodology.

Statewide PPC Performance Trends

Complications Included in Payment Program

Under the All-Payer Model, Maryland hospitals saw a dramatic decline in complications and, as a State, well exceeded the requirement of a 30 percent reduction by the end of CY 2018. These reductions were achieved through clinical quality improvement, as well as improvements in documentation and coding.

As mentioned previously, the MHAC redesign assessed which PPCs should be included in the pay-for-performance program based on criteria developed by the Clinical Adverse Events Measures (CAEM) subgroup that are outlined in the “Monitored Complications” section below.

Under the TCOC Model, Maryland must maintain these improvements by not exceeding the CY 2018 PPC rates for complications included in the payment program. Figure 2 below shows the statewide observed to expected (O/E) ratio from 2018 through June CY 2023.³ The O/E ratio presents the count of observed PPCs divided by the calculated number of expected PPCs (which is generated using statewide normative values applied to the case-mix of discharges a hospital experiences). An O/E Ratio of greater than 1 indicates that a hospital experienced more PPCs than expected, and conversely, an O/E Ratio less than one indicates that a hospital experienced fewer PPCs than expected. Figure 2 below also indicates how Maryland is performing relative to CY 2018, which is the time period that will be used to assess any backsliding on performance.⁴ Specifically, there has been a 27.5 percent decrease in the ratio based on the most recent data available (CY 2018 YTD O/E ratio = 1.09 and CY 2023 YTD O/E ratio = 0.79).

PPCs in the MHAC payment program include:


- 3 Acute Pulmonary Edema and Resp Failure w/o Ventilation
- 4 Acute Pulmonary Edema, Resp Failure w/ventilation
- 7 Pulmonary Embolism
- 9 Shock
- 16 Venous Thrombosis
- 28 In-Hospital Trauma and Fractures
- 35 Septicemia & Severe Infections
- 37 Post-Operative Infection & Deep Wound Disruption Without Procedure
- 41 Peri-Operative Hemorrhage & Hematoma w/ Hemorrhage Control Procedure or I&D
- 42 Accidental Puncture/ Laceration During Invasive Procedure
- 47 Encephalopathy

³ Staff notes that, consistent with federal policies during the COVID Public Health Emergency, PPC data from January-June 2020 will not be used for assessing quality of care.

⁴Beginning in v38 of the 3M PPC grouper, COVID exclusions vary by PPC.


- 49 Iatrogenic Pneumothorax
- 60 Major Puerperal Infection and Other Major Obstetric Complications
- 61 Other Complications of Obstetrical Surgical & Perineal Wounds
- 67 Pneumonia Combo (with and without aspiration)

Figure 2. Payment Program PPCs Observed to Expected Ratios by Quarter CY 2018 to CY 2023 YTD Through June




In terms of specific improvements among the 15 payment PPCs, Figure 3 shows the O/E ratios for CY 2018 and CY 2023 YTD, sorted from greatest percent decrease (on the left) to greatest percent increase (on the right). The two PPCs that worsened during this time period include PPC 47- Encephalopathy and PPC 42- Accidental Puncture/ Laceration During Invasive Procedure. The three PPCs with the greatest decreases (improvements) include PPC 4- Acute Pulmonary Edema and Respiratory Failure with Ventilation, PPC16- Venous Thrombosis, and PPC 67- Combined Pneumonia.

Figure 3. Payment Program PPC Observed to Expected Ratios CY 2018 and CY 2023 June YTD



Staff also analyzed payment PPC changes for FYs 2022 and 2023 compared to the base period of 2018 as illustrated in Figure 4 below. The overall PPC O/E ratios show a steadily declining trend across the three time period; from FY2022 to FY2023 there were 11 PPCs that showed a decrease in the O/E ratios (improvement), and 4 PPCs that showed a slight increase (worsening).


Figure 4. Payment Program PPC Observed to Expected Ratio Trends; CY 2018, FY 2022, and FY 2023



Monitored Complications

In addition to focusing on a narrowed list of PPCs for payment, as stated previously, the RY 2021 MHAC policy following the program redesign included a recommendation to monitor the remaining PPCs. Staff fulfills this recommendation by monitoring all PPCs that are still considered clinically valid by 3M, and distinguishing between “Monitoring” and “Payment” PPCs. The overall PPC trend across all 56 (payment and monitored) PPCs shows that there has been an increase in the overall statewide O/E ratio from 0.85 in CY 2018 to 0.88 in CY 2023 YTD through June; the worsening performance is driven primarily by increases in PPCs under monitoring status, and not increases in the payment program PPCs, as illustrated in Figure 5 below. As also illustrated, the monitored PPC trends have increased from 0.76 as of June YTD 2018 to 0.91 in YTD 2023 with the highest O/E ratios experienced from Q3 2020 to Q1 2021 during the COVID peak period.

Figure 5. PPC O/E Ratio Trends CY 2018 Qtr 1 Through CY 2023 Qtr 2



To provide additional context, the MHAC redesign process assessed which PPCs should be included in the pay-for-performance program based on criteria developed by the Clinical Adverse Events Measures (CAEM) subgroup. To support determining the monitored PPCs that are the best candidates for re-adopting into the payment program, staff and stakeholders are using the previously established criteria that include:

- PPC Data Analysis/Statistics
 - Greater than 50% increase in O/E ratio comparing 2022 to 2018
 - Rate per 1,000 generally 0.5 or above
 - Volume of observed events 100 or above (over two years)

- Significant variation across hospitals O/E ratios less than .85 and greater than 1.15
- At least half of the hospitals are eligible for the PPC
- Additional Considerations
 - PSI overlap
 - Clinical significance
 - Potential influence of coding practices/changes
 - Opportunity for improvement/actionability
 - All-payer

The monitored PPCs with the most significant increases in O/E ratios over time included the PPCs listed below. Staff notes, however, that these PPCs were identified as having limited actionability based on input from stakeholders during the program redesign process; therefore, staff is not recommending that these PPCs be moved into the payment program.

- PPC 8: Other Pulmonary Complications
- PPC 15: Peripheral Vascular Complications except Venous Thrombosis
- PPC 53: Infection, Inflammation and Clotting Complication of Peripheral Vascular and Infusions

Appendix III provides the statewide percentage changes in the O/E ratios for the monitored PPCs from 2018 to 2023 YTD through June sorted by the observed PPCs with the largest increases.

Calculating PPC Performance Standards

Since the RY2021 MHAC Redesign, the performance standards have been the O/E ratio at the 90th (threshold = start to earn points) and 10th (benchmark = full points) percentiles. However, staff are proposing for RY 2026 to modify the methodology slightly to make the performance standards less sensitive to potential outliers by averaging the worst and best performing hospitals (as opposed to taking a single value at a given percentile). This methodology is more in line with the CMS VBP program approach to setting the benchmark. Staff explored a couple of options and suggests averaging the 20 percent of O/E ratios of the worst and best performing hospitals results, which results in similar benchmark and threshold values as compared to the current method but avoids the cliff effects of using a single percentile. See

Appendix IV for additional explanation using the older version of the PPC Grouper and one year of data. Figure 6 shows the results under the current method and potential method using V41 of the PPC Grouper.⁵

Figure 6. Performance Standards Comparisons by Calculation Method

Base FY22 and FY23		Current Method		Proposed Method	
		P90	P10	Avg P80	Avg P20
PPC Number	PPC Description	Threshold	Benchmark	Threshold	Benchmark
3	Acute Pulmonary Edema and Respiratory Failure without Ventilation	1.4858	0.4248	1.9458	0.3844
4	Acute Pulmonary Edema and Respiratory Failure with Ventilation	1.4756	0.1441	2.0135	0.1378
7	Pulmonary Embolism	1.3432	0.1342	1.4736	0.2431
9	Shock	1.874	0.2989	1.8793	0.2747
16	Venous Thrombosis	1.8446	0.2157	1.9665	0.1621
28	In-Hospital Trauma and Fractures	1.6451	0.3822	1.6225	0.3183
35	Septicemia & Severe Infections	1.4583	0.3376	1.6904	0.3397
37	Post-Operative Infection & Deep Wound Disruption Without Procedure	1.4446	0.3896	1.4635	0.3125
41	Peri-Operative Hemorrhage & Hematoma with Hemorrhage Control Procedure or I&D Proc	2.0363	0	2.2026	0.084
42	Accidental Puncture/Laceration During Invasive Procedure	1.6377	0.2539	1.6748	0.2746
47	Encephalopathy	1.9126	0.2282	1.9165	0.2327
49	Iatrogenic Pneumothrax	1.8791	0.4935	1.8856	0.397
60	Major Puerperal Infection and Other Major Obstetric Complications	1.4697	0.3485	1.4697	0.3485
61	Other Complications of Obstetrical Surgical & Perineal Wounds	1.8459	0	1.911	0.0784
67	Combined Pneumonia (PPC 5 and 6)	1.4979	0.1878	1.6807	0.191

Small Hospital Criteria

The current MHAC program handles small hospitals in two ways: 1) Hospitals are excluded from being assessed on a PPC if they do not meet the minimum criteria of 2 expected PPCs and 20 admissions at-risk for a PPC; and 2) Hospital performance is assessed using two years of data if across all 15 payment PPCs the hospital has less than 21,500 at-risk or 22 expected PPCs. For the sepsis PPC, one hospital raised a concern about Criteria 1 that requires a minimum of 2 expected PPCs for the hospital to be assessed on the PPC; this is described more fully in the section just below. Staff is not proposing any global changes to the small hospital criteria.

⁵ These results were updated since the December Performance Measurement Workgroup to V41 of the PPC grouper and two years of “base” data.

PPC Clinical Concerns

Over this past calendar year, hospitals have raised concerns about the small hospital PPC inclusion criteria with regard to the sepsis PPC as well as specific clinical concerns regarding some other PPCs on which they have provided input to 3M for consideration in the annual PPC Grouper updating process.

PPC 35 Septicemia & Severe Infections

One hospital expressed their concerns that they had in previous years been eligible for PPC 35 but had this past year seen their expected rate drop below 2, rendering them ineligible for inclusion of this PPC in their MHAC score. They noted further that the PPC was serious and highly amenable to interventions which they had identified and implemented; however, with the minimum expected criteria of 2, their performance is not counted or recognized in their score. Staff has vetted with the PMWG a proposal that the minimum criteria be waived for PPC 35 Sepsis in light of its seriousness and preventability. While staff are open to stakeholder input on this issue, our initial opinion is that PPCs with small numbers should be removed from the payment program for stability of measurement and that the hospitals still benefit from preventing these complications under the global budget. Stakeholder input on this issue will be summarized in the final policy.

PPC 42: Accidental Puncture or Laceration

Two clinical scenarios of concern were raised for this PPC during RY 2025. For patients with cerebral and spinal dural tissue tears during a surgical procedure when adhesions are present, hospitals provided input that cases with a code indicating adhesions are present should be excluded for this PPC. 3M has agreed with this input and added the code to the exclusion list for this PPC in the Grouper version 41 just released this October. Similarly, hospitals provided input that this PPC should be excluded for patients with abdominal adhesions that have abdominal surgical procedures. 3M is now considering this input and will make a determination to be addressed in Grouper version 42 scheduled for release in October 2024. Staff proposes to address the changes and remove the PPC42 cases of concern retrospectively for RYs 2025 and 2026 by rerunning the PPC data using Grouper version 41 for RY 2025 for PPC 42, and version 42 for RY 2026 if needed. Hospitals will then be given the better of the score for PPC 42 to reflect a clinical issue recognized by 3M during the performance period while not penalizing hospitals retrospectively.

PPC 07- Pulmonary Embolism

For this PPC, hospitals raised concerns that patients with codes indicating a deep vein thrombosis is present should be excluded from being assigned this PPC. 3M has agreed and has updated the exclusion code list for PPC 7 in Grouper version 41. Staff again proposes to address the changes retrospectively and remove the cases of concern from PPC 7 assignment for RY 2025 by rerunning the PPC data using Grouper version 41 and using the better of the scores for each hospital that qualifies for the PPC.

The MHAC final recommendation will provide preliminary analyses on the impact of using v41 of the Grouper for PPC 7 and PPC 42 for RY 2025.

Stability of Case-Mix Adjusted PPC Rates


As Maryland hospitals continue to improve on payment PPCs, staff plan to pursue statistical methods that will better address small cell size issues and statistical reliability and validity. Thus, during CY 2023, staff has begun working with our contractor MPR to explore whether changes are needed to the program. The methods that will be considered are similar to methods used by CMS for the same concerns (i.e., Bayesian smoothing) and modeling has been initially presented to the PMWG during the RY 2026 policy development process. Initial concerns raised by stakeholders have included potential smoothing impact on small hospitals where rates would be driven more by statewide average than the hospitals performance. The HSCRC is exploring different options to address these concerns with our contractor MPR. Staff will continue to develop and model hospital scores with select options for smoothing and vet results with the PMWG during CY 2024 with potential for adoption for the RY 2027 MHAC policy.

Hospital Scores and Revenue Adjustments

The hospital scores are calculated across all payment PPCs and then converted to revenue adjustments using a prospectively determined revenue adjustment scale, which allows hospitals to track their progress throughout the performance period. Since the program redesign, the scale has remained the same—that is it ranges from 0 to 100 percent with a hold-harmless zone between 60 and 70 percent. Despite historical concerns regarding the lack of a continuous scale from some stakeholders, staff still believes that the hold harmless zone is reasonable given the lack of national benchmarks for establishing a cut-point. Using data under v41 of the PPC grouper, staff modeled scores for hospitals using the two methods of setting

performance standards. Overall the change in the approach for determining the performance standards results in equal or higher scores for all but one hospital (i.e., Garrett hospitals score went down by 1 percentage point), with the median increase in scores of 3 percentage points (range -1 to +7 percent). Figure 7 shows the distribution of hospital scores and statistics indicating, for example, that the median score was 63 percent. However, using the current RY 2025 scale, 17 hospitals would receive a penalty, 13 hospitals would be held harmless (i.e., no penalty or reward), and 13 hospitals would receive a reward. Given the average scores are within the hold harmless zone, staff does not recommend changing the current revenue adjustments scale for RY 2026.

Figure 7. Modeled MHAC Scores, SFYs 22-23 Base Period, CY 2023 YTD Through November Performance



Health Equity

Over the past two years, staff began to analyze the quality programs and measures for racial and sociodemographic disparities. Specifically for the MHAC program, the results for the payment PPCs were stratified by race, payer and area deprivation index (ADI) and risk-adjusted for age, sex, Admit-DRG, and Severity of Illness level. Results of this analysis, displayed in Appendix V suggested that there are

statistically insignificant differences between racial categories; however, there were statistically significant differences between payers and ADI categories. While statistically significant differences were found between payers and ADI categories, the odds ratios are relatively low and are, therefore, not an area of large concern for staff compared to the disparities uncovered in other quality measures, for example, Timely Follow-Up. Staff remains committed to addressing health equity, but at this time does not recommend including additional incentives for reducing disparities in PPC performance because of the overall low rates in PPCs and the relatively low odds ratios between payer and ADI categories. Over the next year, Staff will continue to monitor disparities in the quality programs' measures and develop disparity measure(s) and incentives that will drive improvement in disparities.

Stakeholder Feedback and Responses

One comment letter was received from the Maryland Hospital Association stating its support for the draft recommendation. Staff thanks stakeholders, in particular the PMWG members and interested parties, for their engagement and support to update the MHAC policy.

Recommendations

These are the final recommendations for the RY 2026 Maryland Hospital Acquired Conditions (MHAC) program:

1. Continue to use 3M Potentially Preventable Complications (PPCs) to assess hospital acquired complications.
 - a. Maintain a focused list of PPCs in the payment program that are clinically recommended and that generally have higher statewide rates and variation across hospitals.
 - b. Assess monitoring PPCs based on clinical recommendations, statistical characteristics, and recent trends to prioritize those for future consideration for updating the measures in the payment program.
 - c. Engage hospitals on specific PPC increases as indicated/appropriate to understand trends and discuss potential quality concerns.
2. Use more than one year of performance data for small hospitals (i.e., less than 21,500 at-risk discharges and/or 22 expected PPCs). The performance period for small hospitals will be CYs 2023 and 2024.

3. Continue to assess hospital performance on attainment only, with adjustment to performance standards for increased stability.
4. Continue to weight the PPCs in the payment program by 3M cost weights as a proxy for patient harm.
5. Maintain a prospective revenue adjustment scale with a maximum penalty at 2 percent and maximum reward at 2 percent and continuous linear scaling with a hold harmless zone between 60 and 70 percent.
6. Future Considerations:
 1. Assess options for streamlining (or simplifying) the quality programs overall, or for the hospital acquired complication measures that are currently included in both the QBR Safety Domain and the MHAC program.
 2. Assess digitally specified quality measures such as electronic Clinical Quality Measures (eCQMs) for future inclusion in quality programs.

Appendix I. Background on Federal Complication Programs

The Federal Government operates two hospital complications payment programs, the Deficit Reduction Act Hospital Acquired Condition program (DRA-HAC) and the HAC Reduction Program (HACRP), both of which are designed to penalize hospitals for post-admission complications.

Federal Deficit Reduction Act, the Hospital-Acquired Condition Present on Admission Program

Beginning in Federal Fiscal Year 2009 (FFY 2009), per the provisions of the Federal Deficit Reduction Act, the Hospital-Acquired Condition Present on Admission Program was implemented. Under the program, patients were no longer assigned to higher-paying Diagnosis Related Groups if certain conditions were acquired in the hospital and could have reasonably been prevented through the application of evidence-based guidelines.

Hospital-Acquired Condition Reduction Program

CMS expanded the use of hospital-acquired conditions in payment adjustments in FFY 2015 with a new program, entitled the Hospital-Acquired Condition Reduction Program, under the authority of the Affordable Care Act. That program focuses on a narrower list of complications and penalizes hospitals in the bottom quartile of performance. Of note, as detailed in Figure 1 below, all the measures in the Hospital-Acquired Condition Reduction Program are used in the CMS Value Based Purchasing program, and the National Healthcare Safety Network (NHSN) Healthcare-Associated Infection (HAI) measures are also used in the Maryland Quality Based Reimbursement (QBR) program.

Figure 1. CMS Hospital-Acquired Condition Reduction Program (HACRP) FFY 2024 Measures

<p>Recalibrated Patient Safety Indicator (PSI) measure:[^]</p> <ul style="list-style-type: none"> ● PSI 03 – Pressure Ulcer Rate ● PSI 06 – Iatrogenic Pneumothorax Rate ● PSI 08 – In-Hospital Fall with Hip Fracture Rate ● PSI 09 – Perioperative Hemorrhage or Hematoma Rate ● PSI 10 – Postoperative Acute Kidney Injury Requiring Dialysis Rate ● PSI 11 – Postoperative Respiratory Failure Rate ● PSI 12 – Perioperative Pulmonary Embolism or Deep Vein Thrombosis Rate ● PSI 13 – Postoperative Sepsis Rate ● PSI 14 – Postoperative Wound Dehiscence Rate ● PSI 15 – Unrecognized Abdominopelvic Accidental Puncture/Laceration Rate
Central Line-Associated Bloodstream Infection (CLABSI) ^{^*}
Catheter-Associated Urinary Tract Infection (CAUTI) ^{^*}
Surgical Site Infection (SSI) – colon and hysterectomy ^{^*}
Methicillin-resistant Staphylococcus aureus (MRSA) Bacteremia ^{^*}
Clostridium Difficile Infection (CDI) ^{^*}

[^]Recalibrated PSI Composite Measures included in the CMS VBP Program beginning FFY 2023. * National Healthcare Safety Network (NHSN) Healthcare-Associated Infection (HAI) measures included in both the CMS VBP and Maryland QBR Programs

For more information on the DRA HAC program POA Indicator, please refer to:

<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/index>

For more information on the DRA HAC program, please refer to: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/HospitalAcqCond/Downloads/FAQ-DRA-HAC-PSI.pdf>


For more information on the HAC Reduction program, please refer to:

<https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/HAC-Reduction-Program>

Appendix II: RY 2025 MHAC Program Methodology

Figure 1 below provides a summary overview of the approved RY 2025 MHAC methodology.

Figure 1. Overview of RY 2025 Approved MHAC Methodology



Performance Metric

The methodology for the MHAC program measures hospital performance using the Observed (O) /Expected (E) ratio for each PPC. Expected number of PPCs are calculated using historical data on statewide PPC rates by All Patient Refined Diagnosis Related Group and Severity of Illness Level (APR-DRG SOI). See below for details on how the expected number of PPCs are calculated for each hospital.

Observed and Expected PPC Values

The MHAC scores are calculated using the ratio of *Observed* : *Expected* PPC values.

Given a hospital's unique mix of patients, as defined by APR-DRG category and Severity of Illness (SOI) level, the HSCRC calculates the hospital's expected PPC value, which is the number of PPCs the hospital would have experienced if its PPC rate were identical to that experienced by a normative set of hospitals.

The expected number of PPCs is calculated using a technique called indirect standardization. For illustrative purposes, assume that every hospital discharge is considered “at-risk” for a PPC, meaning that all discharges would meet the criteria for inclusion in the MHAC program. All discharges will either have no PPCs, or will have one or more PPCs. In this example, each discharge either has at least one PPC, or does not have a PPC. The unadjusted PPC rate is the percent of discharges that have at least one PPC.

The rates of PPCs in the normative database are calculated for each diagnosis (APR-DRG) category and severity level by dividing the observed number of PPCs by the total number of admissions. The PPC norm for a single diagnosis and severity level is calculated as follows:

Let:

N = norm

P = Number of discharges with one or more PPCs

D = Number of “at-risk” discharges

i = A diagnosis category and severity level

$$N_i = \frac{P_i}{D_i}$$

In the example, each normative value is presented as PPCs per discharge to facilitate the calculations in the example. Most reports will display this number as a rate per one thousand discharges.

Once the normative expected values have been calculated, they can be applied to each hospital. In this example, the normative expected values are computed for one diagnosis category and its four severity levels.

Consider the following example in Figure 2 for an individual diagnosis category.

Figure 2. Expected Value Computation Example for one Diagnosis Category

A Severity of illness Level	B At-risk Discharges	C Observed Discharges with PPCs	D PPCs per discharge (unadjusted PPC Rate)	E Normative PPCs per discharge	F Expected # of PPCs	G Observed: Expected Ratio
			= (C / B)	(Calculated from Normative Population)	= (B x E)	= (C / E) rounded to 4 decimal places
1	200	10	.05	.07	14.0	0.7143
2	150	15	.10	.10	15.0	1.0000
3	100	10	.10	.15	15.0	0.6667
4	50	10	.20	.25	12.5	0.8000
Total	500	45	.09		56.5	0.7965

For the diagnosis category, the number of discharges with PPCs is 45, which is the sum of discharges with PPCs (column C). The overall rate of PPCs per discharge in column D, 0.09, is calculated by dividing the total number of discharges with PPCs (sum of column C) by the total number of discharges at risk for PPCs (sum of column B), i.e., $0.09 = 45/500$. From the normative population, the proportion of discharges with PPCs for each SOI level for that diagnosis category is displayed in column E. The expected number of PPCs for each severity level shown in column F is calculated by multiplying the number of at-risk discharges (column B) by the normative PPCs per discharge rate (column E). The total number of PPCs expected for this diagnosis category is the expected number of PPCs for the severity levels.

In this example, the expected number of PPCs for the APR DRG category is 56.5, which is then compared to the observed number of discharges with PPCs (45). Thus, the hospital had 11.5 fewer observed discharges with PPCs than were expected for 500 at-risk discharges in this APR DRG category. This difference can be expressed as a percentage difference as well.

All APR-DRG categories and their SOI levels are included in the computation of the observed and expected rates, except when the APR-DRG SOI level has less than 30 at-risk discharges statewide.

PPC Exclusions

Consistent with prior MHAC policies, the number of at-risk discharges is determined prior to the calculation of the normative values (hospitals with <10 at-risk discharges are excluded for a particular PPC) and the normative values are then re-calculated after removing PPCs with <2 complication expected. The following exclusions will also be applied:

For each hospital, discharges will be removed if:

- Discharge is in an APR-DRG SOI cell has less than 31 statewide discharges.
- Discharge has a diagnosis of palliative care (this exclusion may be removed in the future once POA status is available for palliative care for the data used to determine performance standards); and
- Discharge has more than 6 PPCs (i.e., a catastrophic case, for which complications are probably not preventable).

For each hospital, PPCs will be removed if during July 2020 to December 2021:

- The number of cases at-risk is less than 15; and
- The expected number of PPCs is less than 1.5.

The PPCs for which a hospital will be assessed are determined using the July 2020 to December 2021 data and not reassessed during the performance period. This is done so that scores can be reliably calculated during the performance period from a pre-determined set of PPCs. The MHAC summary workbooks provide the excluded PPCs for each hospital.

Combination PPCs

Based on clinical input and 3M recommendation, starting in RY 2021 two pneumonia (PPC 5 Pneumonia & Other Lung Infections & PPC 6 Aspiration Pneumonia) PPCs were combined into single pneumonia PPC and the 3M cost weight is a simple average of the two PPC cost weights.

Hospital Exclusions

Acute care hospitals that do not have sufficient volume to have at least 15 at-risk and 1.5 expected for any payment program PPC are excluded from the MHAC policy.

Benchmarks and Thresholds

For each PPC, a threshold and benchmark value are calculated using the determined base period data. In previous rate years when improvement was also assessed, the threshold was set at the statewide median of 1 and the benchmark was the O/E ratio for the top performing hospitals that accounted for 25% of discharges. For RY 2021 under an attainment only methodology, staff adapted the MHAC points system to allow for greater performance differentiation by moving the threshold to the value of the observed to expected ratio at the 10th percentile of hospital performance, moving the benchmark to the value of the observed to expected ratio at the 90th percentile of hospital performance, and assigning 0 to 100 points for each PPC between these two percentile values.

Attainment Points (possible points 0-100)

If the PPC ratio for the performance period is greater than the threshold, the hospital scores zero points for that PPC for attainment.

If the PPC ratio for the performance period is less than or equal to the benchmark, the hospital scores a full 100 points for that PPC for attainment.

If the PPC ratio is between the threshold and benchmark, the hospital scores partial points for attainment.

The formula to calculate the Attainment points is as follows:

- $\text{Attainment Points} = [99 * ((\text{Hospital's performance period score} - \text{Threshold}) / (\text{Benchmark} - \text{Threshold}))] + 0.5$

Calculation of Hospital Overall MHAC Score

To calculate the final score for each hospital, the attainment points earned by the hospital and the potential points (i.e., 100) for each PPC are multiplied by the 3M cost weights. Hospital scores across PPCs are calculated by summing the total weighted points earned by a hospital, divided by the total possible weighted points (100 per PPC * 3M cost weight).

RY 2025 Update: Small Hospital Methodology

Hospital-specific PPC inclusion requirements were updated for the RY 2025 policy, i.e., all hospitals are required to have at least 20 at-risk discharges and 2 expected PPCs in order for a particular PPC to be included in the payment program. Because of the volatility in performance scores for smaller hospitals, the Commission also approved the following policy updates in RY 2025:

“Establish small hospital criteria for assessing performance under the MHAC policy based on the number of at-risk discharges and expected PPCs (i.e., small hospitals are those with less than 21,500 at-risk discharges and/or 22 expected PPCs across all payment program PPCs) as opposed to the number of PPC measure types, and for hospitals that meet small hospital criteria, increase reliability of score by using two years of performance data to assess hospital performance (i.e., for RY 2025 use CY 2022 and 2023). “

Appendix III: Monitoring PPCs

The table below shows the monitored PPCs' O/E ratios for CY 22 YTD (through June) and the percent changes in the observed-to-expected ratio from CY 2018.


Monitoring PPC	2018 O/E	2023 YTD O/E	2018-2023 % Change
25: Renal Failure with Dialysis	1.02	0.31	-69.43%
2: Extreme CNS Complications	1.29	0.47	-63.92
21: Clostridium Difficile Colitis	1.2	0.64	-47.03%
10: Congestive Heart Failure	0.68	0.55	-18.65%
39: Reopening Surgical Site	1	0.88	-11.93%
65: Urinary Tract Infection without Catheter	1.12	0.98	-12.53%
38: Post-Operative Wound Infection & Deep Wound Disruption with Procedure	0.32	0.29	-7.81%
14: Ventricular Fibrillation/Cardiac Arrest	0.74	0.71	-3.51%
11: Acute Myocardial Infarction	0.88	0.85	-2.58%
33: Cellulitis	0.89	0.95	6.08%
40: Peri-Operative Hemorrhage & Hematoma without Hemorrhage Control Procedure or I&D Proc	0.8	0.89	11.65%
24: Renal Failure without Dialysis	0.78	0.94	21.09%
34: Moderate Infections	0.58	0.72	24.28%
19: Major Liver Complications	0.64	0.84	30.47%
66: Catheter-Related Urinary Tract Infection	0.99	1.3	31.50%
20: Other Gastrointestinal Complications without Transfusion or Significant Bleeding	0.65	0.86	32.06%
1: Stroke & Intracranial Hemorrhage	0.67	0.92	38.54%
27: Post-Hemorrhagic & Other Acute Anemia with Transfusion	0.74	1.08	45.23%
8: Other Pulmonary Complications	0.85	1.25	46.36%
48: Other Complications of Medical Care	0.6	0.88	46.79%
45: Post-Procedure Foreign Bodies	1.12	1.74	55.70%
52: Inflammation & Other Complications of Devices, Implants or Grafts Except Vascular Infection	0.7	1.13	60.65%
17: Major Gastrointestinal Complications without Transfusion or Significant Bleeding	0.62	1.01	63.86%
50: Mechanical Complication of Device, Implant & Graft	0.55	0.9	64.49%
26: Diabetic Ketoacidosis & Coma	0.48	0.8	67.05%
29: Poisonings due to Anesthesia	0.82	1.37	67.91%
18: Major Gastrointestinal Complication with Transfusion or Significant Bleeding	0.5	0.84	68.51%
13: Other Cardiac Complications	0.13	0.87	71.54%

Monitoring PPC	2018 O/E	2023 YTD O/E	2018-2023 % Change
59: Medical & Anesthesia Obstetric Complications	0.46	0.82	78.40%
23: GU Complications Except UTI	0.55	0.99	82.26%
54: Infections due to Central Venous Catheters	0.6	1.1	82.59%
53: Infection, Inflammation & Clotting Complications of Peripheral Vascular Catheters & Infusions	0.6	1.1	83.08%
44: Other Surgical Complication- Mod	0.49	0.92	88.42%
15: Peripheral Vascular Complications Except Venous Thrombosis	0.46	0.92	99.92%
51: Gastrointestinal Ostomy Complications	0.47	0.95	102.52%
64: Other In-Hospital Adverse Events	0.49	1.02	106.91%
31: Decubitus Ulcer	0.3	0.81	172.70%
30: Poisonings due to Anesthesia	0 observed	0 Observed	
32: Transfusion Incompatibility Reaction	0 observed	0 Observed	

Appendix IV: Calculating Performance Standards


PPC Variation in Performance

- To understand if there's a need to move to an average approach, staff wanted to understand the variation around the cut points for rewards and penalties
 - Large variation would warrant moving to an average approach



Note: Staff calculations vary from SAS calculations due to rounding differences between SAS and Excel


EX: PPC 47 Variation in Performance



- 10th percentile for benchmark determination appears reasonable
 - Delta between 9th, 10th, and 11th percentile is limited
 - Range between 1st percentile and 20th percentile is limited (~0.4)
 - Average of best ventile is similar to 10th percentile
- 90th percentile for threshold determination appears less reasonable
 - Delta between 89th, 90th, and 91st percentile is more significant
 - Range between 81st percentile and 100th percentile is substantial (~1.5)
 - Average of worst ventile is less similar to 90th percentile


Appendix V: Disparities in PPCs

Below slides are presented by race, payer, and ADI categories that show the odds ratio of experiencing a PPC as well as tables that present the odds ratio, the p-value, and the confidence intervals by category.



PPCs	Odds Ratio Coefficient	P-Value	Confidence Intervals
White (reference)			
Black	1.04	0.113	.9913536 - 1.085907
Hispanic	.88	0.027	.7901786 .9856565
Asian	1.06	0.425	.924325 1.205196
Native Am.	.65	0.151	.3552198 1.173473
Other	1.06	0.341	.9408 1.193
Non-White	1.02	0.312	.9797004 1.066333


Black	1.04	0.123	.9903417	1.084905
Non-Black vs Black (Non-Black reference)	1.04	0.066	.9973128	1.089417



PPCs	Coefficient	P-Value	CI
Medicare (reference)			

PPCs	Coefficient	P-Value	CI
Medicaid	.99	0.836	.916711 1.07284
Commercial	.89	0.000	.8295058 .9482376
Self-Pay/Charity	.68	0.000	.5441243 .8426922
Other	.90	0.117	.7809703 1.027758

PPC by ADI Decile



PPCs	Coefficient	P-Value	CI
1 (reference)			
2	1.10	0.041	1.004006 1.209946
3	1.10	0.053	.9987985 1.2043
4	1.16	0.002	1.054725 1.270863
5	1.19	0.001	1.078814 1.313731
6	1.30	0.000	1.170513 1.449902
7	1.19	0.003	1.063426 1.335627
8	1.33	0.000	1.176754 1.498999

9	1.34	0.000	1.182045 1.520293
10	1.24	0.001	1.088737 1.419777



Maryland
Hospital Association

January 17, 2024

Alyson Schuster, Ph.D.
Deputy Director, Quality Methodologies
Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, Maryland 21215

Dear Dr. Schuster:

On behalf of the Maryland Hospital Association's (MHA) 62 member hospitals and health systems, we appreciate the opportunity to comment on the Health Services Cost Review Commission's (HSCRC) *Draft Recommendations for the Maryland Hospital Acquired Conditions (MHAC) Program for Rate Year (RY) 2026*. We support the staff's recommendations, which are largely unchanged from the existing RY2025 policy.

MHA supports HSCRC's staff recommendation to retain the existing Potentially Preventable Complications (PPCs) in the payment policy and continue to monitor other clinically significant PPCs. Hospitals have significantly decreased the observed-over-expected (O/E) ratio for payment PPCs by more than 27% since 2018. Though, O/E ratios for monitored PPCs rose almost 20% from 2018 through 2023, this represents an improvement of roughly 50 basis points over the last year. Given these findings, MHA supports using the average of the top and bottom 20% O/E ratio results to avoid the cliff effect of using a single percentile for monitoring PPCs. Furthermore, we support the recommendation to use more than one year of performance data for small hospitals.

MHA looks forward to continuing our collaboration with the Commission on this and future policies.

Sincerely,

Brian Sims
Vice President, Quality & Equity

cc: Joshua Sharfstein, M.D., Chairman
Joseph Antos, Ph.D., Vice Chairman
James N. Elliott, M.D.
Ricardo. R. Johnson

Maulik Joshi, DrPH
Adam Kane, Esq.
Nicki McCann, JD
Jonathan Kromm, Ph.D., Executive Director

**Final Recommendations for Establishing
the Emergency Department Potentially Avoidable
Utilization Program for
Rate Year 2026**

February 2, 2024

Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, Maryland 21215
(410) 764-2605
FAX: (410) 358-6217

This document contains the draft staff recommendations for establishing a pay-for-performance incentive for the Emergency Department Potentially Avoidable Utilization Measure for RY 2026. Comments on the draft policy may be submitted by email to hsrc.quality@maryland.gov and are due by 5:00 pm, December 20, 2023.

EXECUTIVE SUMMARY

This document puts forth a draft recommendation for a new Emergency Department Potentially Avoidable Utilization policy, focused on providing all-payer incentives for hospitals to develop alternative care pathways for the most frequent emergency department (ED) visitors.

Draft Recommendations for Rate Year 2026 Emergency Department Potentially Avoidable Utilization Program

1. Implement a Rate Year 2026 pay-for-performance policy incentivizing reduction in ED visits by multi-visit patients (MVPs) on a reward-only and improvement-only basis
2. Set Calendar Year 2023 as the base year.
3. Establish the threshold for performance reward at 5% improvement.
4. Reward hospitals for improvement as follows:
 - a. Calendar Year 2024 improvement of 5-20%: 0.125% of total revenue
 - b. Calendar Year 2024 improvement of >20%: 0.25% of total revenue
5. Require hospitals to prospectively register MVP interventions with the Commission
6. Evaluate reporting to assess health disparities and other unintended consequences

INTRODUCTION

In Calendar Year 2021, the Commission asked staff to begin development of a policy providing hospital payment incentives for reduction of avoidable ED utilization. The rationale for addressing ED utilization includes concerns about cost, volume, and impact on emergency department patient experience. Nationally, avoidable ED visits are estimated to account for 19.6% of ED encounters and \$64.4 billion in costs.¹ ED volume is also recognized as a driver of extended ED length of stay,² which is an important consideration given that Maryland hospitals have some of the longest ED length of stay averages in the nation.


In Calendar Year 2022, staff convened a work group composed of emergency medicine clinicians, hospital representatives and other stakeholders to consider policy options. The group considered a wide variety of policies before concluding that focusing on multi-visit patients would provide hospitals with a well-defined patient population that, due to their frequent presence in the hospital, could be readily targeted with programs offering more effective alternatives to ED care. Participants also took note of several studies detailing successful interventions on multi-visit patients.³⁻⁵

BACKGROUND

To understand the visit volume and cost related to MVPs, staff analyzed inpatient and outpatient casemix data across several years. MVPs were defined as those patients with four or more ED visits in a calendar year. This definition, which has been used commonly in the health services research literature, includes both visits that result in an inpatient admission and those that result in a discharge from the ED.

The analysis found that in 2019 MVPs accounted for 30% of all ED visits, and 32% of ED charges. MVP utilization in 2019 totaled \$326 million. The majority of MVP visits resulted in discharge from the ED, which is consistent with the pattern seen in visits by patients who are not MVPs.

Figure 1: ED visit volume by count of visits by patient in CY 2019




The analysis found that more than 45% of MVPs in 2019 received all of their ED care from a single hospital. The vast majority of MVPs visited one or two hospitals during the year for all of their ED care. When those visits involved multiple hospitals, those hospitals tended to be within the same healthcare system.

Additionally, the analysis found that 67% of MVP visits involved patients with at least one behavioral diagnosis. Behavioral issues also represented the leading principal diagnosis. Other

common principal diagnoses include low-acuity conditions such as back pain, sprains and strains, and other minor injuries. This point is further illustrated by a staff analysis of outpatient MVP visits that found most were assigned triage values indicating lower acuity conditions (Figure 2).

Figure 2: Outpatient ED visit volume with lower acuity (ESI 3,4,5) triage status by year



Finally, the analysis indicated that there is minimal overlap between visits addressed by the current Potentially Avoidable Utilization (PAU) program and the proposed Emergency Department Potentially Avoidable Utilization (ED-PAU) program, both of which include in part and whole, respectively, Prevention Quality Indicators (PQI) that are administered by the Agency for Healthcare Research and Quality (AHRQ). The PAU incentive applies to inpatient stays, and thus excludes roughly four out of five ED visits, because those patients are discharged from the ED without admission. Of the MVPs admitted to the hospital, slightly more than a third meet the PQI specifications in the PAU program. Thus, the Commission can be confident that addressing MVPs will not create incentives that duplicate or compete with those in the existing PAU program.

MEASUREMENT

The goal of the MVP policy is to reduce avoidable ED volume by encouraging hospitals to provide MVPs with more appropriate care pathways, including those focused on behavioral health, end of life care and social needs.

The measurement approach used by the monitoring program used the following definitions.

- **Denominator:** ED claims at a given hospital with a discharge date occurring during the measurement period.
- **Numerator:** Claims in the denominator associated with a patient who has four or more such claims, at any hospital, in the measurement period.

Staff considered an alternate measure definition that would focus on the number of MVPs, rather than the number of visits by MVPs, at a given hospital. However, this would incentivize programs that focus on moving patients across the threshold from four visits to three, leaving significant unmet need among the patients with the highest number of visits. Structuring the policy to focus on visits, rather than patients, encourages hospitals to build programs that target all patients in the MVP population.

Staff also considered whether the MVP criteria should include only visits at the hospital under measurement, or visits across all hospitals. Some hospitals indicated that it would be challenging to identify MVPs other than those who exclusively visit their facility. However, analysis completed by staff suggest that MVPs who visit more than one hospital typically visit other hospitals in the same healthcare system. Thus, system-wide EHR systems can identify patients who are at risk of being included in the MVP measure and flag them for intervention even when they visit multiple hospitals. Leveraging CRISP data can identify such patients when some visits occur outside a given healthcare system. Given these data-sharing features, structuring the policy to focus only on MVPs within a single hospital would needlessly limit the impact of the incentive.

PAYMENT DETAILS

Because the MVP program represents quality measurement in a new domain, and because constraining ED utilization poses the risk of unintended consequences, staff proposes beginning the program with an improvement-only, reward-only payment approach. This will allow staff to

monitor the program for unintended consequences, evaluate improvement under the initial payment structure in conjunction with assessment of other ED programs, and propose changes as necessary at the end of CY 2024.

Staff also considered the relationship between ED-PAU and the Marketshift and Efficiency policies. Performance under the current PAU program is intentionally excluded from the Marketshift methodology in order to ensure that the incentives do not work at cross purposes. If PAU volume was included in Marketshift, hospitals could potentially see funding shifted to another hospital if PAU increased at that facility but decreased at their own, thus offsetting any reward under the MVP program. To avoid this dynamic, staff recommend carving out of the Marketshift methodology ED services associated with MVPs.

The Efficiency policy has a variety of interactions with the existing PAU methodology. Staff will further explore how to incorporate ED PAU into Efficiency in future workgroup discussions.

REPORTING REQUIREMENTS

In order to be eligible for rewards, hospitals will be required to prospectively register their MVP interventions with the Commission, using a form that will be developed by Commission staff. Data collected will be used to assess the effectiveness of various types of interventions.

FUTURE UPDATES

Staff will produce monitoring reports stratifying MVP status and performance at the hospital level by race, payer, gender, Area Deprivation Index, and age group in an effort to prevent the MVP program from furthering existing healthcare disparities.

STAKEHOLDER FEEDBACK

Stakeholder Comment Letters were received from:

- Maryland Hospital Association (MHA)
- Johns Hopkins Health System (JHHS)

- MedStar Health
- Meritus Health
- MedStar and JHHS support the overall policy and recommended modifications.
- MHA opposed the policy but supports a voluntary program with infrastructure funding that incentivizes meaningful regional partnerships and sustainable health care programs.
- Meritus Health expressed concern that the program could result into the unintended consequence of incentivizing hospitals to reduce access to care for the most vulnerable patients

Stakeholder Concern: Policy Scope

- The recommendation is singularly focused on hospitals without any intention to engage payers, state and local governments. (JHHS)
- The policy should be more intentionally focused on a single disease that truly represents avoidable care. (JHHS)
- The ED PAU program alone will not address the other factors external to the hospital which have been proven to be the drivers of high MVPs (MHA).
- The policy will unfairly hold hospitals accountable for systematic issues outside of their control. (MHA)

Staff Response: The HSCRC's mandate is to regulate hospitals. Stakeholders are welcome to engage other actors in the health sector to improve performance on the MVP measure.

Restricting the program to a single diagnosis would limit the impact of the program on ED length of stay and Total Cost of Care Model performance, while also preventing hospitals from developing programs that would be most beneficial to the populations they serve.

There are numerous examples in the peer-reviewed literature of hospital-based programs that have been successful in addressing MVPs, so failing to incentivize hospitals to implement such programs would be a missed opportunity.

Stakeholder Concern: Ceiling Effect

- When financial incentives for reducing PAU are applied, it will be difficult to keep making incremental progress as PAU percentages decline.

- Similarly, hospitals with high percentages of PAU will be provided more opportunity to achieve financial reward than hospitals who have already achieved low levels of ED PAU (MedStar).
- The policy rewards all volume reduction and views all ED volume as addressable even though there is ED MVP utilization that is appropriate and medically necessary (JHHS and Meritus).

Staff Response: Staff acknowledge that even the best-performing EDs will have some MVPs. Given that most hospitals have not implemented programs aimed at identifying more effective care pathways for MVPs, it is likely that there is significant room for improvement before this becomes an issue. Staff will monitor policy results. Development of an attainment policy component could occur at that point. Attainment incentives would also provide benefits to hospitals that have already invested in addressing the MVP issue. Staff will explore approaches to provide equitable opportunity under the policy for hospitals that significantly reduced MVP volume prior to the implementation of the policy.

Stakeholder Concern: Unintended Consequences

- The policy recommendation incentivizes a reduction in care options for marginalized groups (MHA).
- Within the current model, hospitals that reduce or entirely eliminate services are rewarded, while hospitals that provide medically necessary care – or take on volume that was shed by other hospitals, are penalized (JHHS).

Staff Response: The intent of the policy is to incentivize hospitals to develop more effective care pathways for MVPs and by extension for marginalized groups. Staff will develop and monitor access to care metrics to ensure the policy has the intended effect. The Market Shift policy ensures that appropriate financial accommodation is made when shifts in patient volume occur across facilities. Moreover, there are several policy mechanisms in addition to the Market Shift policy that the Commission currently employs to ensure that hospitals are not rewarded for rationing care: a capped corridor policy that doesn't allow hospitals to recoup the entire global budget unless 95 percent of volumes are provided; a deregulation policy that removes funding from hospitals if volumes are relocated to a unregulated setting; and the Integrated Efficiency policy that negatively scales inflation for hospitals that have relatively poor performance in

hospital cost per case assessments and total cost of care, which can be largely driven by excess retained revenue.

Stakeholder Suggestions and Staff Comments

- The focus in the ED should be on improving ED wait times and throughput. (Meritus Health)
 - The MVP policy is one component of the State's response to the ED performance issue. While improving ED throughput and securing additional inpatient resources for ED patients are important, reducing the number of patients visiting the ED remains a key part of the solution.
- Hospital analyses have shown that some MVPs travel farther to seek care at specific hospitals, while others do not have the option to seek care elsewhere. (JHHS)
 - The policy's improvement methodology minimizes the impact of this and other differences in patient populations between hospitals.
- Instead of MVP, HSCRC should create a voluntary program with infrastructure funding that incentivizes meaningful regional partnerships and sustainable programs to address the needs of patients. (MHA)
 - A voluntary program will be insufficient to address the current magnitude of the ED performance challenge in the state, and is not responsive to the Commission's original request to staff
- In order to maximize the effectiveness of the ED PAU Policy, CRISP data will need to be made available in an easy to understand and user-friendly report so hospitals can track MVPs across hospitals in Maryland (MedStar).
 - HSCRC will work with CRISP and hospitals on this.
- Commitment from HSCRC staff this policy is not intended to include downside financial risk (MedStar)

- Per HSCRC policy, staff do not make commitments on the future structure of financial programs. If significant improvement is observed under the reward-only approach, there would be little justification for changing the policy.

Final Recommendations for Rate Year 2025 Emergency Department Potentially Avoidable Utilization Program

1. Implement a Rate Year 2026 pay-for-performance policy incentivizing reduction in MVP visits on a reward-only and improvement-only basis
2. Set Calendar Year 2023 as the base year.
3. Establish the threshold for performance reward at 5% improvement.
4. Reward hospitals for improvement as follows:
 - a. Calendar Year 2024 improvement of 5-20%: 0.125% of total revenue
 - b. Calendar Year 2024 improvement of >20%: 0.25% of total revenue
5. Require hospitals to prospectively report initiation of programs addressing MVP to be eligible for rewards
6. Develop reporting to assess health disparities

Appendix I: References

1. Galarraga, J. E. & Pines, J. M. Costs of ED episodes of care in the United States. *Am. J. Emerg. Med.* **34**, 357–365 (2016).
2. Morley, C., Unwin, M., Peterson, G. M., Stankovich, J. & Kinsman, L. Emergency department crowding: A systematic review of causes, consequences and solutions. *PLoS One* **13**, e0203316 (2018).
3. Althaus, F. *et al.* Effectiveness of interventions targeting frequent users of emergency departments: a systematic review. *Ann. Emerg. Med.* **58**, 41–52.e42 (2011).
4. Soril, L. J. J., Leggett, L. E., Lorenzetti, D. L., Noseworthy, T. W. & Clement, F. M. Reducing frequent visits to the emergency department: a systematic review of interventions. *PLoS One* **10**, e0123660 (2015).
5. Tsai, M.-H. *et al.* Reducing High-Users' Visits to the Emergency Department by a Primary Care Intervention for the Uninsured: A Retrospective Study. *Inquiry* **55**, 46958018763917 (2018).
6. Ma Z.B., Khatri, R.P., Buehler, G., Boutwell, A., Tseng, K. (2023). Transforming Care Delivery and Outcomes for Multivisit Patients. *NEJM* 4(7)
7. Althaus F., Paroz S., Hugli O., Ghali W.A., Daeppen J., Peytremann-Bridevaux I., Bodenmann P. (2011). Effectiveness of Interventions targeting frequent users of Emergency Departments: a systematic review. *Ann Emerg Med.* Jul;58(1):41-52.e42



Meritus Health
11116 Medical Campus Rd
Hagerstown, MD 21742
301.790.8000

January 3, 2024

Jon Kromm, Ph.D.
Executive Director
Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, Maryland 21215

Subject: Meritus Health comments on the ED Multi-Visit Patient measure recommended for RY 2026

Dear Dr. Kromm:

Thank you to the HSCRC for the focus on quality and efficiency in Maryland. Specific to the measure and the rewards-only approach for the multi-visit patients (MVP), we have some concerns noted below and have a suggested option. The focus on the emergency department (ED) is critical and we need to find better ways to address patient needs in a setting other than the ED when able. Our thoughts are as follows:

1. The focus in the ED should be on improving ED wait times and throughput. Based on feedback we receive, our patients and community care about the ED wait times primarily – the time from when you arrive to the ED and are discharged home or admitted to the hospital. This view on improving ED wait times is a statewide theme. Reducing multi-visit patients is intended to reduce ED volume and, thus ED wait times. We appreciate this direction, however, would suggest that we focus only on ED wait times as a payment-related measure since it is our primary outcome of interest.
2. Based upon our Meritus data from the last twelve months ending 11/30/23 (This represents over 70,000 emergency room visits):
 - a. MVP patients are more likely to have Medicaid (30% for MVP patients compared to 23% for non-MVP patients),
 - b. MVP patients present to the ED with a higher acuity (31.0% MVP patient visits with an ESI 1 or 2 – emergent or urgent, compared to 26.3% for non-MVP patient visits)
 - c. MVP patients are more likely to be admitted (31.5% for MVP patients compared to 21.4% for non-MVP patients).

This indicates that our MVP patients may be the patients that are in most need of these acute services. We caution the unintended consequence of incentivizing hospitals to reduce the access to ED care for these patients, our most vulnerable patients. We certainly recognize the need to develop more robust access in other care settings, such as primary care and urgent care, however, these are not new strategies for us, or other hospitals. The reality is that expanding primary and urgent care is a challenge with a growing physician shortage, especially in

underserved areas. We would be happy to share our data in depth if it assists in further analysis statewide.

3. Some options for your consideration:

- a. Track this measure, be transparent with the outcomes, and re-evaluate after year one. Depending on the findings from year one and the state-wide performance on ED wait time improvement, then consider the establishment of this measure as a reward-based program. Or,
- b. Use the ED wait time measure as a trigger measure for the reward. If the hospital's ED wait time is not decreased, then there should be no reward if there is an MVP reduction.

We appreciate the HSCRC's consideration of our thoughts and look forward to continuing to work with you toward better health and quality outcomes for our patients.

Sincerely,

A handwritten signature in black ink, appearing to read "Carrie Adams". The signature is fluid and cursive, with the first name "Carrie" being more prominent than the last name "Adams".

Carrie Adams, PharmD
Chief Operating Officer



January 5, 2024

Geoff Dougherty
Deputy Director, Population Health
Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, Maryland 21215

Dear Mr. Dougherty,

On behalf the Johns Hopkins Health System (JHHS) and its four Maryland hospitals, thank you for the opportunity to provide input on the Emergency Department Potentially Avoidable Utilization (ED PAU) policy. JHHS supports the concept of developing strategies and accountability for multi-visit patients (MVPs), and encourages the development of policies that align with the intent of the Maryland Model. JHHS's comments and concerns regarding the ED PAU recommendation are detailed below.

JHHS agrees that hospitals should be actively engaged in addressing the needs of multi-visit patients. However, JHHS is also concerned that the current recommendation is singularly focused on hospitals without any effort or intention to engage state and local government as well as Medicaid fee-for-service and Managed Care Organizations and insurers, who are paid to manage the care of the members they serve. Commercial insurers remain the biggest benefactors of the Maryland Model, and their contribution to issues such as ED PAU should be required and measured. Collaboration and accountability for MVPs should extend beyond hospitals alone to generate meaningful change and improvement for Marylanders. As noted by the HSCRC and Maryland Department of Health in the 2016 Population Health paper submitted to CMMI, socio-economic factors such as housing, employment and education account for 40% of health care cost and utilization. Hospitals alone cannot address the lack of focus and investment in these socio-economic factors.

Though the current recommendation is reward-only, it is also crucial to note that the policy as written may have unintended consequences that are similar to other distortions that exist under the Maryland Model. As JHHS has previously noted, the model currently rewards any and all volume reduction, and views all ED volume as addressable. However, there is and will continue to be some ED MVP utilization that is appropriate and medically necessary. Within the current model, hospitals that reduce or entirely eliminate services are rewarded, while hospitals that provide medically necessary care – or take on volume that was shed by other hospitals – are penalized. This approach does not align with the goals of the model, and could be further exacerbated by the ED PAU policy, as the proposed policy could potentially reward hospitals that limit access to care. Further, the policy does not recognize

patient preference and experience. JHHS's analyses reflect that some MVPs travel farther to seek care at specific hospitals, while others do not have the option to seek care elsewhere. JHHS urges staff to account for these additional distortions and considerations when revising the current ED PAU recommendation.

JHHS recommends that staff initiate an ED PAU policy that is limited and more intentionally focused on a single disease that truly represents avoidable care. This policy should require collaboration across multiple stakeholders, including hospitals, state and local government, commercial insurers, and MCOs. Additionally, hospitals should report on their strategies to address MVP utilization to ensure hospitals who may perform well under the policy are not achieving positive results by limiting access in order to decrease volumes. If the policy is more intentionally focused on addressable ED MVP volume, the HSCRC and the industry can then use lessons learned from the initial policy to address additional diseases or conditions in future years. While behavioral health represents the greatest opportunity to improve care for MVPs, it is important to note that the MCOs and hospitals have limited opportunity to improve care for this population under Maryland's existing Medicaid financing for behavioral health. Behavioral health is carved out of MCOs and generally "unmanaged" for the Medicaid population, which accounts for 40% of ED MVPs. Strategies to improve behavioral health care for MVPs should include a fully integrated Medicaid program.

JHHS appreciates the efforts and partnership of the HSCRC staff as the Commission and industry seek to develop intentional strategies to support the needs of multi-visit patients. While supportive of the intent of the policy, JHHS encourages a thoughtful approach to ensure new policy methodologies align with the goals of the Maryland Model, and looks forward to further discussion and collaboration on this policy.

Sincerely,



Peter Hill, MD

Senior Vice President - Medical Affairs
Johns Hopkins Health System

cc: Joshua Sharfstein, MD, Chairman
Joseph Antos, PhD
Nicki McCann, JD
Ricardo Johnson, JD

Maulik Joshi, DrPH
James Elliott, MD
Adam Kane, Esq.,



Maryland
Hospital Association

January 5, 2024

Geoff Dougherty
Deputy Director, Population-Based Methodologies, Analytics, and Modeling
Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, Maryland 21215

Dear Mr. Dougherty:

On behalf of the Maryland Hospital Association's (MHA) 62 member hospitals and health systems, we appreciate the opportunity to comment in opposition to the Health Services Cost Review Commission's (HSCRC) *Draft Recommendations for the Emergency Department Potentially Avoidable Utilization Program for Rate Year (RY) 2026*.

Over the last several months, we have valued the opportunity to collaborate with stakeholders including the HSCRC staff to bring light and focus on the critically important issue of emergency department (ED) utilization and overcrowding. It has allowed all partners to discuss and agreed that this issue is multi-faceted and a symptom of a larger issue in the health care continuum including lack of primary care and behavioral health access, hospital throughput, post-acute availability and services, and state and payer administrative policies and procedures that overcrowd our state's emergency departments. As we work with the Legislative Workgroup for final recommendations for systematic change, hospitals continue to do the performance improvement work to address the hospital specific issues we can control through the EDDIE project.

Unfortunately, the current draft recommendations for the emergency department potentially avoidable utilization program do not help to achieve the aims of addressing the problems of emergency department overcrowding. Specifically,


- It is well-established that patterns of repeated ED utilization are often a function of deficiencies within a public health system and compromised access to alternative sites of care. A policy that focuses solely on hospitals, even if it is reward only, cannot and will not address the services lacking in the community.
- HSCRC data shows a disproportionate number of individuals identified as a multi-visit patient (MVP) are members of marginalized groups. Until we can adequately meet the primary care and social needs of these groups outside of the hospital setting, we oppose a payment policy that incentivizes a reduction in care options for marginalized groups.
- The draft policy sets a precedent of holding hospitals accountable for systematic issues outside of the hospitals' control. Without a comprehensive and coordinated approach that brings all stakeholders together, using hospital rate-setting sets an unfair expectation for hospitals.

We believe a more holistic approach to addressing multi-visit patients would be to create a grant program similar to the Regional Partnership Catalyst Program to provide resources and incentives for hospitals to continue and expand their work with community-based organizations, state agencies, and payers to help Marylanders access more appropriate pathways for care and/or other upstream solutions. Through public/private partnerships, all the stakeholders can work collaboratively to address the goals outlined in the staff recommendations and the complex needs of individuals who frequently return to hospital emergency rooms. A grant program can allow for accountability to be appropriately shared and evaluated, refined, and scaled as needed over time.

Therefore, we oppose the current policy as written and support a voluntary program with infrastructure funding that incentivizes meaningful regional partnerships and sustainable programs to address the needs of our patients.

We look forward to collaborating with staff and partners statewide to improve care for all Marylanders.

Sincerely,



Brian Sims
Vice President, Quality & Equity

cc: Joshua Sharfstein, M.D., Chair
Joseph Antos, Ph.D., Vice Chair
James N. Elliott, M.D.
Ricardo. R. Johnson

Maulik Joshi, DrPH
Adam Kane, Esq.
Nicki McCann, JD
Jonathan Kromm, Ph.D., Executive Director

From: **White, David H** <David.H.White@medstar.net>

Date: Fri, Jan 5, 2024 at 5:12 PM

Geoff,

The key points that will be reflected in MedStar's comment letter on behalf of our seven Maryland hospitals on the ED PAU Reduction Policy for RY2026 are as follows:

MedStar is supportive of the policy overall and agrees with the development of new financial incentives to drive improvement in ED wait times as the issue has been of central focus since the pandemic. In alignment with staff's conclusions, MedStar agrees that this patient population (MVPs) poses an opportunity to significantly impact ED throughput and patient wait times through directing these patients to a more appropriate care setting outside the ED. Realizing that these patients are who needs to be the focus when reducing ED PAU, MedStar has already implemented a number of programs designed to devote increased care management resources to these patients and treat them in the appropriate setting and has been successful in reducing the number of MVPs frequenting our EDs.

- 1.
2. MedStar does not believe that financial rewards should be determined on an improvement only basis vs the 2023 calendar year base period. When financial incentives for reducing PAU for first implemented in Maryland hospitals were able to achieve significant success early on once resources were intentionally devoted to the efforts and then as PAU percentages declined found it more difficult to keep making incremental progress. (Hospitals were able to get the low hanging fruit so to speak and then it became for challenging). Similarly, with ED PAU hospitals who have high percentages of avoidable utilization will be provided more opportunity to achieve financial reward than hospitals who have already achieved low levels of ED PAU. The incremental reduction in PAU is much harder to achieve at hospitals who have already implemented strategies and whose EDs run efficiently. MedStar wants a policy that incentivizes in the strongest way possible reductions in ED PAU as well as rewards those hospitals who have historically been effective in treating MVPs in more appropriate settings. Actions taken by MedStar to achieve low levels of ED PAU have benefited patients by reducing wait times and improving care outcomes and have helped limit Total Cost of Care Growth. Any policy financially incentivizing ED PAU reductions should reward these efforts and successes.
3. Data Sharing – to maximize the effectiveness of the ED PAU Policy, CRISP data will need to be made available in an easy to understand and user-friendly report so hospitals can track MVPs across hospitals in Maryland. While we can track them within our system, frequently they do not only seek care at one health systems hospitals.
4. Commitment from HSCRC staff this policy is not intended to include downside financial risk.

All the best,
Dave White
Director, Reimbursement Strategy & Methodologies
MedStar Health



maryland
health services
cost review commission

Draft Recommendation for the Readmission Reduction Incentive Program for Rate Year 2026

February 14, 2024

This document contains staff draft recommendations for the RY 2026 Readmission Reduction Incentive Program; comments are due by COB Wednesday, February 21, 2024 and may be submitted to hscrc.quality@maryland.gov.

Table of Contents

List of Abbreviations	2
Key Methodology Concepts and Definitions	3
Policy Overview	4
Recommendations	5
Introduction	6
Background	7
Brief History of RRIP program	7
RRIP Methodology	8
Assessment	9
Current Statewide Year To Date Performance	10
Medicare FFS performance	10
All-Payer Readmission Performance	11
Updating the Performance Targets Under the TCOC Model	14
Improvement	14
Attainment	17
Revisits to Emergency Department and Observation Stays	18
Excess Days in Acute Care (EDAC)	18
Digital Measures/Electronic Clinical Quality Measure (eCQM)	19
Reducing Disparities in Readmissions	20
Recommendations	23
Appendix I. RRIP Readmission Measure and Revenue Adjustment Methodology	1
Appendix II. Analyses of Medicare Readmissions	9

List of Abbreviations

ADI	Area Deprivation Index
AMA	Against Medical Advice
APR-DRG	All-patient refined diagnosis-related group
CMS	Centers for Medicare & Medicaid Services
CMMI	Center for Medicare and Medicaid Innovation
CRISP	Chesapeake Regional Information System for Our Patients
CY	Calendar year
eCQM	Electronic Clinical Quality Measure
EDAC	Excess Days in Acute Care
FFS	Fee-for-service
HCC	Hierarchical Condition Category
HRRP	Hospital Readmissions Reduction Program
HSCRC	Health Services Cost Review Commission
HWR	Hospital-Wide Readmission Measure
MCDB	Medical Claims Database
MPR	Mathematica Policy Research
MSA	Metropolitan Statistical Area
NQF	National Quality Forum
PAI	Patient Adversity Index
PMWG	Performance Measurement Workgroup
PQI	Prevention Quality Indicators
RRIP	Readmissions Reduction Incentive Program
RY	Rate Year
SIHIS	Statewide Integrated Healthcare Improvement Strategy
SOI	Severity of illness
TCOC	Total Cost of Care
YTD	Year-to-date

Key Methodology Concepts and Definitions

Diagnosis-Related Group (DRG): A system to classify hospital cases into categories that are similar in clinical characteristics and in expected resource use. DRGs are based on a patient's primary diagnosis and the presence of other conditions.

All Patients Refined Diagnosis Related Groups (APR-DRG): Specific type of DRG assigned using 3M software that groups all diagnosis and procedure codes into one of 328 All-Patient Refined-Diagnosis Related Groups.

Severity of Illness (SOI): 4-level classification of minor, moderate, major, and extreme that can be used with APR-DRGs to assess the acuity of a discharge.

APR-DRG SOI: Combination of diagnosis-related groups with severity of illness levels, such that each admission can be classified into an APR-DRG SOI "cell" along with other admissions that have the same diagnosis-related group and severity of illness level.

Observed/Expected Ratio: Readmission rates are calculated by dividing the observed number of readmissions by the expected number of readmissions. Expected readmissions are determined through case-mix adjustment.

Case-Mix Adjustment: Statewide rate for readmissions (i.e., normative value or "norm") is calculated for each diagnosis and severity level. These statewide norms are applied to each hospital's case-mix to determine the expected number of readmissions, a process known as indirect standardization.

Prevention Quality Indicator (PQI): a set of measures that can be used with hospital inpatient discharge data to identify quality of care for "ambulatory care sensitive conditions." These are conditions for which good outpatient care can potentially prevent the need for hospitalization or for which early intervention can prevent complications or more severe disease.

Area Deprivation Index (ADI): A measure of neighborhood deprivation that is based on the American Community Survey and includes factors for the theoretical domains of income, education, employment, and housing quality.

Patient Adversity Index (PAI): HSCRC-developed composite measure of social risk incorporating information on patient race, Medicaid status, and the Area Deprivation Index.

Excess Days in Acute Care (EDAC): Capture excess days that a hospital's patients spent in acute care within 30 days after discharge. The measures incorporate the full range of post-discharge use of care (emergency department visits, observation stays, and unplanned readmissions).

Policy Overview

Policy Objective	Policy Solution	Effect on Hospitals	Effect on Payers/Consumers	Effect on Health Equity
<p>The quality programs operated by the Health Services Cost Review Commission, including the Readmission Reduction Incentive Program (RRIP), are intended to ensure that any incentives to constrain hospital expenditures under the Total Cost of Care Model do not result in declining quality of care. Thus, HSCRC’s quality programs reward quality improvements and achievements that reinforce the incentives of the Total Cost of Care Model, while guarding against unintended consequences and penalizing poor performance.</p>	<p>The RRIP policy is one of several pay-for-performance quality initiatives that provide incentives for hospitals to improve and maintain high-quality patient care and value over time.</p>	<p>The RRIP policy currently holds up to 2 percent of hospital revenue at-risk for performance relative to predetermined attainment or improvement goals on readmissions occurring within 30-days of discharge, applicable to all payers and all conditions and causes. Specific criteria for inclusion (oncology discharges) and exclusion (discharges leaving Against Medical Advice, Planned Admissions) are detailed in Appendix I.</p>	<p>This policy affects a hospital’s overall GBR and so affects the rates paid by payers at that particular hospital. The HSCRC quality programs are all-payer in nature and so improve quality for all patients that receive care at the hospital.</p>	<p>Currently, the RRIP policy measures within-hospital disparities in readmission rates, using an HSCRC-generated Patient Adversity Index (PAI), and provides rewards for hospitals that meet specified disparity gap reduction goals. The broader RRIP policy continues to reward or penalize hospitals on the better of improvement and attainment, which incentivizes hospitals to improve poor clinical outcomes that may be correlated with health disparities. It is important that persistent health disparities are not made permanent.</p>

Recommendations

These are the draft recommendation for the Maryland Rate Year (RY) 2026 Readmission Reduction Incentives Program (RRIP):

1. Maintain the 30-day, all-cause readmission measure.
2. Improvement Target - Set statewide 4-year improvement target of -5.5 percent from 2022 base period through 2026.
3. Attainment Target - Maintain the attainment target whereby hospitals at or better than the 65th percentile of statewide performance receive scaled rewards for maintaining low readmission rates.
4. Maintain maximum rewards and penalties at 2 percent of inpatient revenue.
5. Provide additional payment incentive (up to 0.50 percent of inpatient revenue) for reductions in within-hospital readmission disparities. Scale rewards:
 - a. beginning at 0.25 percent of IP revenue for hospitals on pace for 50 percent reduction in disparity gap measure over 8 years, and;
 - b. capped at 0.50 percent of IP revenue for hospitals on pace for 75 percent or larger reduction in disparity gap measure over 8 years.
6. Monitor emergency department and observation revisits by adjusting readmission measure and through all-payer Excess Days in Acute Care measure. Consider future inclusion of revisits of EDAC in the RRIP program.

Introduction

Maryland hospitals are funded under a population-based revenue system with a fixed annual revenue cap set by the Maryland Health Services Cost Review Commission (HSCRC or Commission) under the All-Payer Model agreement with the Centers for Medicare & Medicaid Services (CMS) beginning in 2014, and continuing under the current Total Cost of Care (TCOC) Model agreement, which took effect in 2019. Under the global budget system, hospitals are incentivized to shift services to the most appropriate care setting and simultaneously have revenue at risk in Maryland's unique, all-payer, pay-for-performance quality programs; this allows hospitals to keep any savings they earn via better patient experiences, reduced hospital-acquired infections, or other improvements in care. Maryland systematically revises its quality and value-based payment programs to better achieve the state's overarching goals: more efficient, higher quality care, and improved population health. It is important that the Commission ensure that any incentives to constrain hospital expenditures do not result in declining quality of care. Thus, the Commission's quality programs reward quality improvements and achievements that reinforce the incentives of the global budget system, while guarding against unintended consequences and penalizing poor performance.

The Readmissions Reduction Incentive Program (RRIP) is one of several quality pay-for-performance initiatives that provide incentives for hospitals to improve patient care and value over time that targets unplanned readmissions. While some hospital readmissions are unavoidable, other hospital readmissions within 30 days result from ineffective initial treatment, poor discharge planning, or inadequate post-acute care and result in poor patient outcomes and financially straining healthcare institutions.¹ The RRIP currently holds up to 2 percent of hospital revenue at-risk in penalties and rewards based on achievement of improvement or attainment targets in 30-day case-mix adjusted readmission rates.

For RRIP, as well as the other State hospital quality programs, updates are vetted with stakeholders and approved by the Commission to ensure the programs remain aggressive and

¹ Rammohan R, Joy M, Magam S, et al. (May 15, 2023) The Path to Sustainable Healthcare: Implementing Care Transition Teams to Mitigate Hospital Readmissions and Improve Patient Outcomes. *Cureus* 15(5): e39022. doi:10.7759/cureus.39022

progressive with results that meet or surpass those of the national CMS analogous programs (from which Maryland must receive annual exemptions). For purposes of the RY 2026 RRIP Draft Policy, staff vetted the updated proposed recommendations in January with the Performance Measurement Workgroup (PMWG), the standing advisory group that meets monthly to discuss Quality policies.

Additionally, with the onset of the Total Cost of Care Model Agreement, each program was overhauled to ensure they support the goals of the Model. For the RRIP policy, the overhaul was completed during 2019, which entailed an extensive stakeholder engagement effort. The major accomplishments of the RRIP redesign were modifications to the inclusion and exclusion criteria for the readmission measure, development of a 5-year (2018-2023) improvement target, adjustment of the attainment target, and the addition of an incentive to reduce within hospital disparities in readmissions. See Appendix I for additional information on the Readmission Redesign Subgroup activities.

This draft policy recommends a new four-year improvement target (CY2022 to CY2026), assesses the current attainment target, discusses the issue of revisits to the emergency department/observation following an inpatient admission, and continues the incentive for reductions in within-hospital disparities. The draft policy does not recommend any changes to the current case-mix adjustment readmission measure, and minimal updates to the disparity gap measurement. Given the multi-year nature of this policy, staff may extend this policy for multiple years unless changes are warranted.

Background

Brief History of RRIP program

Maryland made incremental progress each year throughout the All-Payer Model (2014-2018), ultimately achieving the Model goal for the Maryland Medicare FFS readmission rate to be at or below the unadjusted national Medicare readmission rate by the end of Calendar Year (CY) 2018. Maryland had historically performed poorly compared to the nation on readmissions; it ranked

50th among all states in a study examining Medicare data from 2003-2004.² In order to meet the All-Payer Model requirements, the Commission approved the inaugural RRIP program in April 2014 to further bolster the incentives to reduce unnecessary readmissions beyond the incentives already inherent in the global budget system.

As recommended by the Performance Measurement Work Group (PMWG), the RRIP is more comprehensive than its federal counterpart, the Medicare Hospital Readmission Reduction Program (HRRP), as it is an all-cause, all-condition measure that includes all eligible discharges regardless of payer.³ Furthermore, it assesses both improvement and attainment and provides an incentive to focus on disparities.

RRIP Methodology


Figure 1 provides an overview of the current RRIP methodology (also see Appendix I) that converts hospital performance to payment adjustments. In Maryland, the RRIP methodology evaluates all-payer, all-cause inpatient readmissions using the CRISP unique patient identifier to track patients across Maryland hospitals. The readmission measure excludes certain types of discharges (pediatric oncology, patients who leave against medical advice, rare diagnosis groups) from consideration, due to data issues and clinical concerns. Readmission rates are adjusted for case-mix using all-patient refined diagnosis-related group (APR-DRG) severity of illness (SOI), and the policy determines a hospital's score and revenue adjustment by the better of improvement or attainment.⁴ The disparity gap methodology is separate and provides hospitals with the opportunity to earn rewards (no penalties) based on improvement.

² Jencks, S. F. et al., "Hospitalizations among Patients in the Medicare Fee-for-Service Program," *New England Journal of Medicine* Vol. 360, No. 14: 1418-1428, 2009.

³ For more information on the HRRP, please see: <https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/Readmissions-Reduction-Program>

⁴ See Appendix I for details of on the current RRIP methodology.

Figure 1. RRIP Methodology RY25



Assessment

For RY 2026, the main policy decision is to develop a new improvement target, since the original TCOC model goal was set through CY 2023. In order to set a new improvement goal, this section assesses readmissions performance and provides improvement scenarios for consideration. While there are no proposed changes to the readmission measure, staff are recommending that additional analytics be conducted over the coming year to assess hospital revisits to the emergency department and/or observation, which staff believes will complement some of the other workstreams the Commission currently

is engaging in to improve emergency room length of stay. Finally, staff provides performance on the disparity gap measure and recommends to continue this targeted focus on high adversity patients.


Current Statewide Year To Date Performance

Readmission performance is assessed in several ways. First, we present data on the unadjusted, all-cause Medicare Readmission Rate (the “Waiver Test”), which shows that Maryland currently has a slightly higher unadjusted readmission rate than the nation. Second, we present the all-payer, case mix adjusted readmission results used for the RRIP.

Medicare FFS performance

At the end of 2018, Maryland had an unadjusted FFS Medicare readmission rate of 15.40 percent, which was below the national rate of 15.45 percent. This is the measure that CMMI used to assess Maryland’s successful performance on readmissions under the All-payer Model. Under the TCOC model, Maryland is required to maintain a Medicare FFS readmission rate that is below the nation. However, since CY 2021, Maryland’s FFS Medicare unadjusted readmission rate has hovered slightly above that of the nation. The most recent readmission data, in Figure 2, show Maryland’s readmission rate at 15.69 percent with the nation at 15.42 percent. However, as discussed in Appendix II, staff and CMMI have agreed to move to a risk-adjusted readmission measure that takes into account the case-mix differences between Maryland and the Nation. Overall, when taking case-mix into account, Maryland Medicare FFS patients have a lower readmission rate than National beneficiaries.


Figure 2. Maryland and National Medicare FFS Unadjusted Readmission Rates



All-Payer Readmission Performance

Maryland has also performed well statewide over time on RRIP performance standards as shown in Figure 3, with All-payer, Medicare FFS, and Medicaid MCO readmission reductions of 6.64 percent, 4.90 percent and 10.58 percent from 2018 respectively. The all-payer reduction is in line with the 5-year improvement goal, which was set as part of the RRIP redesign, of a 7.5 percent improvement from CY2018 through CY2023.

Figure 3. Statewide Improvement in Case-Mix Adjusted Readmission Rates by Payer, 2018 through 2023 YTD



Most hospitals continue to perform well under the RY 2025 RRIP program, which is based on CY 2023 performance (current results are YTD through October). As illustrated in Figure 4 below, 16 hospitals are on target to reach the improvement goal of 7.5 percent, and as shown in Figure 5, 13 hospitals are on target to have a readmission rate below the benchmark of 11.32 percent. Hospitals performing well on both improvement and attainment will receive the better revenue adjustment (i.e., the higher reward or lower penalty). Overall there are 22 unique hospitals on track to receive a scaled reward for CY 2023 performance, which staff believe is reasonable given the continued improvements and that on a risk-adjusted basis the state is meeting the CMMI target.

Figure 4. By-Hospital Change in All-Payer Case Mix Adjusted Readmission Rates, 2018-YTD 2023





Figure 4. By-Hospital Change Case Mix Adjusted Readmission Rates, YTD 2023



Updating the Performance Targets Under the TCOC Model

Improvement

Maryland hospitals achieved the contractual test for Medicare readmissions to be at or below the nation by 2018. Analyses conducted as part of the RRIP redesign suggested that further improvements of 7.5 percent could be achieved. This draft policy repeats the analyses conducted in 2019 to determine whether additional improvement should be expected over the last few years of the TCOC model, and a reasonable improvement goal for earning rewards.

Staff believe that further reductions in readmissions are possible, but recommend a more modest improvement target from CY 2022 through CY2026 in recognition of the sustained and substantial

improvement under the All-Payer Model and the first five years under the TCOC Model. As the literature does not provide an optimal all-payer readmission rate, staff have generated a range of potential improvement scenarios. While the final policy will contain additional benchmarking and may update some of the analyses below, Figure 5 provides the initial analyses completed by staff. These analyses yield readmission rate reductions of approximately 4-9 percent from existing CY 2022 levels.

Figure 5. Improvement Target Estimates

Estimating Method	Percent Improvement	Resulting Readmission Rate (2026)*
1 Actual Compounded Improvement, 2018-2022	-8.61%	10.19%
2 Actual Improvement 2021-2022, Annualized to Four Years	-5.54%	10.53%
3 All Hospitals to 2018 Median	-4.1%	10.69%
4a Medicare Benchmarking - Peer County/MSA to 75th Percentile**	-4.75% to -5.45%	TBD
4b Commercial Benchmarking - Peer County/MSA to 75th Percentile**	TBD	TBD
5 Reduction in Readmission-PQIs	TBD	TBD
6 Reduction in Disparities	TBD	TBD

* Assuming a constant CY 2022 readmission rate of 11.38 percent (under RY 2024 logic with specialty hospitals included)

**Appendix IV details the Commercial and Medicare benchmarking work done throughout 2019 to inform the readmission improvement and attainment target setting.

For the first estimating method (Row 1), staff analyzed the improvement achieved under the first four years of the TCOC model and assumed that similar improvements could be repeated during

the last four years under the TCOC Model. This ~9 percent reduction represents the higher end of the improvement estimates. The second method (Row 2) uses the (slightly slower) improvement achieved between 2021 and 2022 and annualizes this one-year improvement to four years, resulting in a slightly less aggressive improvement target of ~5.5 percent.

The third and fourth estimating methods derive targets by assuming that hospitals currently performing worse than the statewide median or other peer geographies could improve to these rates. The third method (Row 3) calculates the statewide improvement if all hospitals are reduced to the CY 2022 median readmission rate. This method provides the lowest improvement goal currently calculated. The fourth estimating method (Row 4) uses national benchmarks of like geographies to generate improvement targets for Maryland hospitals to reduce to the 75th percentile of similar geographies. Currently, this benchmarking data is only available for Medicare; however, staff anticipate adding data on commercial benchmarking for the final policy. Based on 2022 data, Maryland Medicare FFS readmission rates would need to improve by 4.75 percent to reach the Peer county 75th best percentile (15.23 percent to 14.96 percent), or 5.75 percent to ensure that all Maryland counties were at or below the 75th percentile (15.23 percent to 14.40 percent).⁵ Currently staff are working to finalize the commercial benchmarking analysis to include in the final policy.

The fifth method will estimate what the readmission rate would be if a certain percent of readmissions that are also PQIs (i.e., avoidable admissions for conditions such as diabetes, COPD, and hypertension) are prevented. The last method on the chart will estimate what the readmission rate would be if hospitals in the state with higher than average disparities reduced their readmission disparity gap to the statewide average. Again these analyses will be presented in the final policy and may change the currently proposed improvement goal.

These scenarios identify a range of potential targets but do not determine a specific, optimal readmission rate.. Staff and stakeholders agree generally with the range of potential improvement targets and support the generation of a four-year target rather than annual targets. Stakeholders

⁵ The second scenario is lower as there are Maryland counties already better than the 75th percentile.

also continue to support including both improvement and attainment in building a revenue adjustment. Reviewing the range of potential targets, the improvement from CY 2018 experienced to-date in CY 2022, and the additional information from the benchmarking, staff feels comfortable to recommend an improvement target of 5.5 percent reduction from 2022 levels across four years, but will follow up in the final policy recommendation with an assessment of what a 5.5 percent improvement will mean for the State's Medicare casemix adjusted readmission rate relative to national comparators. Staff also reserves the right to revisit and revise this target should it prove too aggressive or too lenient such that the state creates unintended consequences or risks not meeting the continued goal of remaining at or below that national Medicare rate.

Attainment

Prior to the RRIP Redesign for the TCOC model, the HSCRC has used the 75th percentile of best performers as the threshold to begin receiving rewards for attainment. In RY 2021, this was amended to the 65th percentile to allow hospitals in the top-third of Maryland performance to earn financial rewards for attainment, which acknowledged that Maryland (historically a poor performer on readmissions) had accomplished substantial improvement during the All-Payer Model. Staff analyzed the historical policy of the 65th percentile and compared this to the improvement targets suggested by the MEDA Center Peer Group national benchmarking analysis and the various opportunity analyses. Ultimately, staff calculated the statewide CY 2018 casemix-adjusted rate inclusive of 7.5% improvement and compared individual hospital CY 2018 readmission rates to this figure. Staff determined that at the 65th percentile of current performance, hospitals have rates equivalent to the targeted statewide readmission rate. Once the improvement modeling is finished, staff will repeat this analysis using the statewide CY 2022 readmission rates plus the improvement target and compare that rate to the 65th percentile of hospital performance in CY 2022. Depending on the results, staff will make a final decision on the attainment target; however, for now in this draft policy we are keeping the 65th percentile as the goal and in general believe that rewarding the top third of hospital performance is reasonable.

Revisits to Emergency Department and Observation Stays

Improvement in readmission rates under the model should result in better patient experience. However, the current readmission measures only count a readmission if the patient returns to the hospital and is admitted into an inpatient bed. Thus, revisits to the emergency department or for an observation stay after an initial inpatient admission are not considered. This potentially has an impact on hospital throughput and ED boarding as anecdotally ED hospital staff have said that they are doing more testing and diagnostics in the ED that previously may have been done during the inpatient admission to determine whether an admission is really necessary. While this might be appropriate clinically, if these revisits represent quality of care or care coordination concerns, these are not being identified for payment incentives at this time (only exception is PAU includes observation stays ≥ 24 hours as inpatient stays). When staff have looked at this previously for just observation stays, we found that while readmission rates increased when observation stays were included, the correlation between the readmission rates with and without observation stays was 0.986 in 2018. This analysis, and the fact that the national program does not include observation stays, led the staff at that time to recommend that the RRIP readmission measure remain an inpatient only measure. However, staff are recommending in this draft policy, and are looking for Commissioner input/support, to repeat these analyses with both ED and observation stays included to assess the extent of revisits, types of revisits, and differential impacts of revisits on readmission performance by hospital (i.e., does the rank order of hospitals change with inclusion of revisits). While PMWG members have told us that revisits do reflect quality of care or other concerns such as medication access, they do remain concerned about lack of benchmarking for a broader measure.

Excess Days in Acute Care (EDAC)

As discussed above, stakeholders remain concerned about emergency department and observation revisits, especially given the global budget incentives to avoid admissions. Another approach for addressing this issue would be to adopt the Excess Days in Acute Care measure into payment. The EDAC measure captures the number of days that a patient spends in the hospital within 30 days of discharge, and includes emergency department and observation stays by assigning ED visits a half-day length of stay and assigning observation hours rounded up to half-day units.⁶ Staff have worked with our methodological contractor to adapt the Medicare

⁶ Additional information on the EDAC measures and methodology can be found here: <https://www.qualitynet.org/inpatient/measures/edac/methodology>

Excess Days in Acute Care (EDAC) condition-specific measures to an all-cause, all-payer measure for potential program adoption in future years. This work was completed and monitoring reports for this measure are posted on the CRISP portal on a monthly basis for hospital monitoring and input. Over the coming year if staff is directed to assess revisits, the EDAC measure may be one option for consideration rather than adapting the actual readmission measure. However, the EDAC measure has been criticized by some PMWG members because of the time element associated with the readmission. Specifically, the concern is that longer readmissions (which would represent worse performance) may indicate a less preventable readmission. While staff will consider this concern, it could also be countered that a longer readmission represents a more serious quality of care issue from the initial admission.

Digital Measures/Electronic Clinical Quality Measure (eCQM)

Under the Inpatient Quality Reporting program, CMS transitioned from the claims-based 30-day Hospital Wide Readmission (HWR) measure to the digital Hybrid HWR measure with the July, 1 2023-June 30, 2024 mandatory reporting of the hybrid measure for Medicare patients for FFY 2026 payment year. The HWR 30-day readmission hybrid measure merges electronic health record data elements with a set of 13 Core Clinical Data Elements (CCDE) consisting of six vital signs and seven laboratory test results; hospitals must map these 13 CCDE to the patient electronic health record (EHR). The claims and CCDE data are then submitted and used to calculate measure results. For the initial mandatory year beginning July 1, 2023, HSCRC also requires hospitals to submit the hybrid HWR measure data to the State for Medicare patients. Additionally, staff has formally communicated to hospitals the State's intent to expand the measure to all-payers and to patients aged 18 and above beginning with July 1, 2024 discharges. To prepare for this update, CRISP and Medisolv (CRISP digital measure subcontractor) have indicated they are updating the data collection infrastructure and will be ready to receive data on the expanded measure with the first submission scheduled to begin in January 2025. However, in a digital measures stakeholder subgroup staff convened in August 2023, and in subsequent communication with staff, hospital and EHR vendor representatives have raised significant concerns about the feasibility of expanding the measure beyond Medicare patients. Among the specific concerns from hospitals are, in some cases, their EHR vendors are telling them there are additional costs and significant effort to set up and implement the expanded measure; in other

cases, hospitals are noting their EHR vendor is telling them they are unable to do the work to expand and implement the measure. HSCRC staff will continue to investigate the issues voiced by hospitals and identify strategies to progress on expansion of the Hybrid measure, and will also consider options for augmenting the RRIP all-payer measure with EHR data elements in the future.

Reducing Disparities in Readmissions

Racial and socioeconomic differences in readmission rates are well documented^{7,8} and have been a source of significant concern among healthcare providers and regulators for years. In Maryland, the 2018 readmission rate for blacks was 2.6 percentage points higher than for whites, and the rate for Medicaid enrollees was 3.4 points higher than for other patients. A 2019 *Annals of Internal Medicine* paper co-authored by HSCRC staff⁹ reported a 1.6 percent higher readmission rate for patients living in neighborhoods with increased deprivation. Maryland hospitals, as well as CMS and the Maryland Hospital Association, identify reduction in disparities as a key priority over the near term. Thus, staff developed and the Commission approved adding a within-hospital disparity gap improvement goal to the RRIP in RY2021.

Specifically, the RRIP within hospital disparity methodology assesses patient-level socioeconomic exposure using the Patient Adversity Index (PAI), a continuous measure that reflects exposure to poverty, structural racism, and neighborhood deprivation. As shown in Figure 6, the relationship between PAI and readmissions is then assessed for each hospital for the base and performance period, and improvements in the slope of the line or in the difference in readmission rates at two points on the line (e.g., PAI = 1 vs PAI = 0) are compared for the base and performance period to calculate improvement. Hospitals that improve on the within hospital disparity gap and improve on overall readmissions, are eligible for a scaled reward up to 0.50 percent of inpatient revenue.


⁷ Tsai TC, Orav EJ, Joynt KE. Disparities in surgical 30-day readmission rates for Medicare beneficiaries by race and site of care. *Ann Surg*. 2014;259(6):1086–1090. doi:10.1097/SLA.0000000000000326;

⁸ Calvillo–King, Linda, et al. "Impact of social factors on risk of readmission or mortality in pneumonia and heart failure: systematic review." *Journal of general internal medicine* 28.2 (2013): 269-282.

⁹ Jencks, Stephen F., et al. "Safety-Net hospitals, neighborhood disadvantage, and readmissions under Maryland's all-payer program: an observational study." *Annals of internal medicine* 171.2 (2019): 91-98.

Additional information on the development of the within-hospital disparity metric can be found in the RY 2021 RRIP policy.¹⁰

Figure 6. Hypothetical Example of Relationship between PAI and Readmission Rates



The RRIP disparity gap improvement goal was set through the end of the TCOC model (CY2026) and aligns with one of the goals in the Statewide Integrated Improvement Strategy. The SIHIS goal is to have half of eligible hospitals achieve a 50 percent reduction in readmission disparities. CY 2022 data shows that 32 hospitals saw a reduction in their within-hospital disparities in readmissions, ranging from a 0.18% reduction to a 61.54% reduction. Through the RY2024 RRIP-Disparity Gap Program (CY 2022 performance), scaled rewards were provided to 11 of these

¹⁰ ADD FOOTNOTE WITH LINK TO POLICY

hospitals for reducing their disparities in readmissions by the required minimum of 22.89 percent while simultaneously reducing their overall readmission rate; the range of revenue adjustments was 0.26 percent to 0.5 percent for a statewide total of about \$7.8 million in rewards. To meet the CY 2023 SIHIS Target, the State needs at least 22 hospitals to reduce their within-hospital disparities in readmissions by 25 percent. The State remains committed to ensuring hospitals are advancing health equity by continuing to financially incentivize reductions in disparities through the Readmissions Reduction Incentive Program (RRIP) policy and other policies. The ability to set hospital payment incentives specifically for advancing health equity is an important hallmark of the TCOC Model and exemptions from national quality programs. In the RY 2026 Quality Based Reimbursement program, this disparity gap methodology was adapted to the Timely Follow-Up post hospitalization measure and the Commission approved financial incentives for reductions in disparities in follow up for Medicare patients.

Post-COVID there have been some updates to the disparity gap methodology for readmissions. First, HSCRC staff updated the measure to use post-COVID CY 2021 norms that are applied to both the historical CY 2018 data, as well as to the performance periods. However, in doing this, staff decided that in order to fully measure improvement, all of the regression model coefficients used for risk-adjustment such as diagnosis-severity of illness, age, and sex (not just the PAI coefficient) should be “locked in” or not recalculated for each time period. This technical change ensures any improvement over time is fully captured, rather than only capturing improvement above the state average improvement (which would make the SIHIS goal challenging). Staff are working to lock model coefficients from the CY 2021 base period to be applied to the performance period, but initial analyses show this has only a minor impact on results. These updates to the RRIP-Disparity Gap methodology, however, are important for stakeholder engagement.

For RY 2026, the RRIP disparity gap draft recommendation uses the previously calculated improvement targets pushed forward to CY 2024 performance. Staff continue to work with hospitals to help them understand this methodology and are planning to conduct a learning session on the methodology in March. This learning session will review the methodology and model scenarios to show how certain interventions that focus on high adversity patients to reduce readmissions impacts the measure.

Recommendations

These are the draft recommendation for the Maryland Rate Year (RY) 2026 Readmission Reduction Incentives Program (RRIP):

7. Maintain the 30-day, all-cause readmission measure.
8. Improvement Target - Set statewide 4-year improvement target of -5.5 percent from 2022 base period through 2026.
9. Attainment Target - Maintain the attainment target whereby hospitals at or better than the 65th percentile of statewide performance receive scaled rewards for maintaining low readmission rates.
10. Maintain maximum rewards and penalties at 2 percent of inpatient revenue.
11. Provide additional payment incentive (up to 0.50 percent of inpatient revenue) for reductions in within-hospital readmission disparities. Scale rewards:
 - a. beginning at 0.25 percent of IP revenue for hospitals on pace for 50 percent reduction in disparity gap measure over 8 years, and;
 - b. capped at 0.50 percent of IP revenue for hospitals on pace for 75 percent or larger reduction in disparity gap measure over 8 years.
12. Monitor emergency department and observation revisits by adjusting readmission measure and through all-payer Excess Days in Acute Care measure. Consider future inclusion of revisits of EDAC in the RRIP program.

Appendix I. RRIP Readmission Measure and Revenue Adjustment Methodology

Introduction: RRIP Redesign Subgroup

As part of the ongoing evolution of the All-Payer Model's pay-for-performance programs to further bring them into alignment under the Total Cost of Care Model, HSCRC convened a work group to evaluate the Readmission Reduction Incentive Program (RRIP). The work group consisted of stakeholders, subject matter experts, and consumers, and met six times between February and September 2019. The work group focused on the following six topics, with the general conclusions summarized below:

1. Analysis of Case-mix Adjustment and trends in Eligible Discharges over time to address concern of limited room for additional improvement;
 - Case-mix adjustment acknowledges increased severity of illness over time
 - Standard Deviation analysis of Eligible Discharges suggests that further reduction in readmission rates is possible
2. National Benchmarking of similar geographies using Medicare and Commercial data;
 - Maryland Medicare and Commercial readmission rates and readmissions per capita are on par with the nation
3. Updates to the existing All-Cause Readmission Measure;
 - Remove Eligible Discharges that left against medical advice (~7,500 discharges)
 - Include Oncology Discharges with more nuanced exclusion logic
 - Analyze out-of-state ratios for other payers as data become available
4. Statewide Improvement and Attainment Targets under the TCOC Model;
 - 7.5 percent Improvement over 5 years (2018-2023)
 - Ongoing evaluation of the attainment threshold at 65th percentile
5. Social Determinants of Health and Readmission Rates; and
 - Methodology developed to assess within-hospital readmission disparities
6. Alternative Measures of Readmissions
 - Further analysis of per capita readmissions as broader trend; not germane to the RRIP policy because focus of evaluation is clinical performance and care management post-discharge
 - Observation trends under the All-Payer Model to better understand performance given variations in hospital observation use; future development will focus on incorporation of Excess Days in Acute Care (EDAC) measure in lieu of including observations in RRIP policy
 - Electronic Clinical Quality Measure (eCQM) may be considered in future to improve risk adjustment

Methodology Steps

1) Performance Metric

The methodology for the Readmissions Reduction Incentive Program (RRIP) measures performance using the 30-day all-payer all hospital (both intra- and inter-hospital) readmission rate with adjustments for patient severity (based upon discharge all-patient refined diagnosis-related group severity of illness [APR-DRG SOI]) and planned admissions.¹¹ Unique patient identifiers from CRISP are used to be able to track patients across hospitals for readmissions.

The measure is similar to the readmission rate that is calculated by CMMI to track Maryland performance versus the nation, with some exceptions. The most notable exceptions are that the HSCRC measure includes psychiatric patients in acute care hospitals, and readmissions that occur at specialty hospitals. In comparing Maryland's Medicare readmission rate to the national readmission rate, the Centers for Medicare & Medicaid Services (CMS) will calculate an unadjusted readmission rate for Medicare beneficiaries. Since the Health Services Cost Review Commission (HSCRC) measure is for hospital-specific payment purposes, an additional adjustment is made to account for differences in case-mix. See below for details on the readmission calculation for the RRIP program.

2) Inclusions and Exclusions in Readmission Measurement

- Planned readmissions are excluded from the numerator based upon the CMS Planned Readmission Algorithm V. 4.0. The HSCRC has also added all vaginal and C-section deliveries and rehabilitation as planned using the APR-DRGs, rather than principal diagnosis.¹² Planned admissions are counted as eligible discharges in the denominator, because they could have an unplanned readmission.
- Discharges for newborn APR-DRG are removed.¹³
- Exclude bone marrow transplants and liquid tumor patients by making these discharges not eligible to have an unplanned readmission or count as an unplanned readmission.¹⁴
- Exclude patients with a discharge disposition of Left Against Medical Advice (PAT_DISP = 71, 72, or 73 through FY 2018; 07 FY 2019 onward)
- Rehabilitation cases as identified by APR-860 (which are coded under ICD-10 based on type of daily service) are marked as planned admissions and made ineligible for readmission after readmission logic is run.
- Admissions with ungroupable APR-DRGs (955, 956) are not eligible for a readmission, but can be a readmission for a previous admission.
- APR-DRG-SOI categories with less than two discharges statewide are removed.
- A hospitalization within 30 days of a hospital discharge where a patient dies is counted as a readmission; however, the readmission is removed from the denominator because the case is

¹¹ Planned admissions defined under [CMS Planned Admission Logic version 4 – updated March 2018].

¹² **Rehab DRGs:** 540, 541, 542, 560, and 860; **OB Deliveries and Associated DRGs:** 580, 581, 583, 588, 589, 591, 593, 602, 603, 607, 608, 609, 611, 612, 613, 614, 621, 622, 623, 625, 626, 630, 631, 633, 634, 636, 639, 640, and 863.

¹³ **Newborn APR-DRGs:** 580, 581, 583, 588, 589, 591, 593, 602, 603, 607, 608, 609, 611, 612, 613, 614, 621, 622, 623, 625, 626, 630, 631, 633, 634, 636, 639, 640, and 863.

¹⁴ **Bone Marrow Transplant:** Diagnosis code Z94.81 or CCS Procedure code 64; **Liquid Tumor:** Diagnosis codes C81.00-C96.0. See section below for additional details on the oncology logic.


not eligible for a subsequent readmission.

- Admissions that result in transfers, defined as cases where the discharge date of the admission is on the same or next day as the admission date of the subsequent admission, are removed from the denominator. Thus, only one admission is counted in the denominator, and that is the admission to the transfer hospital (unless otherwise ineligible, i.e., died). It is the second discharge date from the admission to the transfer hospital that is used to calculate the 30-day readmission window.
- Beginning in RY 2019, HSCRC started discharges from chronic beds within acute care hospitals.
- In addition, the following data cleaning edits are applied:
 - Cases with null or missing CRISP unique patient identifiers (EIDs) are removed.
 - Duplicates are removed.
 - Negative interval days are removed.

HSCRC staff is revising case-mix data edits to prevent submission of duplicates and negative intervals, which are very rare. In addition, CRISP EID matching benchmarks are closely monitored. Currently, hospitals are required to make sure 99.5 percent of inpatient discharges have a CRISP EID.

Additional Details on Oncology Logic:

Flow Chart for Revised Oncology Logic



*Items that are **bolded** are adaptations from NQF measure

This updated logic replaces the RY 2021 measure logic that removes all oncology DRGs from the dataset, such that an admission with an oncology DRG cannot count as a readmission or be eligible to have a readmission.

Step 1: Exclude discharges where patients have a bone marrow transplant procedure, bone marrow transplant related diagnosis code, or liquid tumor diagnosis. This logic varies from the NQF cancer hospital measure that risk-adjusts for bone marrow transplant and liquid tumors. HSCRC

staff recommended removing these discharges (similar to current DRG exclusion) because the current indirect standardization approach did not allow for additional risk-adjustment but based on conversations with clinicians staff agreed these cases were significantly more complicated and at-risk for an unpreventable readmission.

Step 2: Flag discharges with a primary malignancy diagnosis to apply cancer specific logic for determining readmissions. This varies from the NQF cancer hospital measure that flags patients with primary or secondary malignancy diagnosis being treated in a cancer specific hospital. Staff think we should only flag those with a primary diagnosis since in a general acute care hospital there may be differences in the types of patients with a secondary malignancy diagnosis. Further, we remove the bone marrow and liquid tumor discharges regardless of malignancy diagnosis, thus ensuring the most severe cases are removed. Last, our initial analyses did not show a large impact on overall hospital rates when primary vs primary and secondary malignancies were flagged. It should be noted however that the current modeling in this policy uses readmission rates where both primary and secondary are flagged.

Step 3: Flag planned admissions using additional criteria beyond the CMS planned admission logic:

- a) Nature of admission of urgent or emergent considered unplanned, all other nature of admission statuses are planned
- b) Any admission with primary diagnosis of chemotherapy or radiation is considered planned
- c) Any admission with primary diagnosis of metastatic cancer is not considered preventable, and thus gets excluded from being a readmission

In step 3, admissions are deemed not eligible to be a readmission but they are eligible to have a subsequent unplanned readmission.

3) Details on the Calculation of Case-Mix Adjusted Readmission Rate

Data Source:

To calculate readmission rates for RRIP, inpatient abstract/case-mix data with CRISP EIDs (so that patients can be tracked across hospitals) are used for the measurement period, with an additional 30 day runout. To calculate the case-mix adjusted readmission rate for CY 2018 base period and CY 2023 performance period, data from January 1 through December 31, plus 30 days in January of the next year are used. CY 2021 data are used to calculate the normative values, which are used to determine a hospital's expected readmissions, as detailed below, as well as the estimated CY 2018 readmission rates.

Please note that, the base year readmission rates are not "locked in", and may change if there are CRISP EID or other data updates. The HSCRC does not anticipate changing the base period data, and does not

anticipate that any EID updates will change the base period data significantly; however, the HSCRC has decided the most up-to-date data should be used to measure improvement. For the performance period, the CRISP EIDs are updated throughout the year, and thus, month-to-month results may change based on changes in EIDs.

SOFTWARE: APR-DRG Version 41 for CY 2018-CY 2024.

Calculation:

$$\text{Case-Mix Adjusted Readmission Rate} = \frac{\text{(Observed Readmissions) Readmission Rate}}{\text{(Expected Readmissions) Readmission Rate}} * \text{Statewide Base Year}$$

Numerator: Number of observed hospital-specific unplanned readmissions.

Denominator: Number of expected hospital specific unplanned readmissions based upon discharge APR-DRG and Severity of Illness. See below for how to calculate expected readmissions, adjusted for APR-DRG SOI.

Risk Adjustment Calculation:

Calculate the Statewide Readmission Rate without Planned Readmissions.

- o Statewide Readmission Rate = Total number of readmissions with exclusions removed / Total number of hospital discharges with exclusions removed.

For each hospital, enumerate the number of observed, unplanned readmissions.

For each hospital, calculate the number of expected unplanned readmissions at the APR-DRG SOI level (see Expected Values for description). For each hospital, cases are removed if the discharge APR-DRG and SOI cells have less than two total cases in the base period data.

Calculate at the hospital level the ratio of observed (O) readmissions over expected (E) readmissions. A ratio of > 1 means that there were more observed readmissions than expected, based upon a hospital's case-mix. A ratio of < 1 means that there were fewer observed readmissions than expected based upon a hospital's case-mix.

Multiply the O/E ratio by the base year statewide rate, which is used to get the case-mix adjusted readmission rate by hospital. Multiplying the O/E ratio by the base year state rate converts it into a readmission rate that can be compared to unadjusted rates and case-mix adjusted rates over time.

Expected Values:

The expected value of readmissions is the number of readmissions a hospital would have experienced had its rate of readmissions been identical to that experienced by a reference or normative set of hospitals, given its mix of patients as defined by discharge APR-DRG category and SOI level. Currently, HSCRC is using state average rates as the benchmark.

The technique by which the expected number of readmissions is calculated is called indirect standardization. For illustrative purposes, assume that every discharge can meet the criteria for having a readmission, a condition called being “eligible” for a readmission. All discharges will either have zero readmissions or will have one readmission. The readmission rate is the proportion or percentage of admissions that have a readmission.

The rates of readmissions in the normative database are calculated for each APR-DRG category and its SOI levels by dividing the observed number of readmissions by the total number of eligible discharges. The readmission norm for a single APR-DRG SOI level is calculated as follows:

Let:

N = norm

P = Number of discharges with a readmission

D = Number of eligible discharges

i = An APR DRG category and a single SOI level

$$N_i = \frac{P_i}{D_i}$$

For this example, the expected rate is displayed as readmissions per discharge to facilitate the calculations in the example. Most reports will display the expected rate as a rate per one thousand.

Once a set of norms has been calculated, the norms are applied to each hospital's DRG and SOI distribution. In the example below, the computation presents expected readmission rates for a single diagnosis category and its four severity levels. This computation could be expanded to include multiple diagnosis categories, by simply expanding the summations.

Consider the following example for a single diagnosis category.

Expected Value Computation Example – Individual APR-DRG



A Severity of Illness Level	B Eligible Discharges	C Discharges with Readmission	D Readmissions per Discharge (C/B)	E Normative Readmissions per Discharge	F Expected # of Readmissions (A*E)
1	200	10	.05	.07	14.0
2	150	15	.10	.10	15.0
3	100	10	.10	.15	15.0
4	50	10	.20	.25	12.5
Total	500	45	.09		56.5

For the diagnosis category, the number of discharges with a readmission is 45, which is the sum of discharges with readmissions (column C). The overall rate of readmissions per discharge, 0.09, is calculated by dividing the total number of eligible discharges with a readmission (sum of column C) by the total number of discharges at risk for readmission (sum of column B), i.e., $0.09 = 45/500$. From the normative population, the proportion of discharges with readmissions for each severity level for that diagnosis category is displayed in column E. The expected number of readmissions for each severity level shown in column F is calculated by multiplying the number of eligible discharges (column B) by the normative readmissions per discharge rate (column E). The total number of readmissions expected for this diagnosis category is the sum of the expected numbers of readmissions for the 4 severity levels.

In this example, the expected number of readmissions for this diagnosis category is 56.5, compared to the actual number of discharges with readmissions of 45. Thus, the hospital had 11.5 fewer actual discharges with readmissions than were expected for this diagnosis category. This difference can also be expressed as a percentage or the O/E ratio.

4) Revenue Adjustment Methodology

The RRIP assesses improvement in readmission rates from base period, and attainment rates for the performance period with an adjustment for out-of-state readmissions. The policy then determines a hospital's revenue adjustment for improvement and attainment and takes the better of the two revenue adjustments, with scaled rewards of up to 2 percent of inpatient revenue and scaled penalties of up to 2 percent of inpatient revenue. The figure below provides a high level overview of the RY 2025 RRIP methodology for reference.



Appendix II. Analyses of Medicare Readmissions

Based on analyses, HSCRC staff believe that patients admitted in Maryland have gotten sicker since 2018 (i.e., higher rate of comorbidities) and that this increase in case mix acuity is greater in Maryland than the increase seen nationally. These analyses support what hospitals have reported anecdotally. To examine the change in patient case mix over time from 2018 through 2022, HSCRC staff first used the CCW data to estimate readmission risk in 2018. Then, the annual predicted readmission risk was calculated for CYs 2019 through 2022 by applying the 2018 coefficients for each comorbidity. Changes in the predicted readmission rates indicate that there are differences in the population at-risk for readmissions. Specifically, increases in the predicted readmission rate would indicate that the at-risk population was composed of patients with comorbidities or other risk factors with a higher risk of readmission. Decreases in the predicted readmission rate would indicate the at-risk population was composed of patients with lower risk for readmission than in 2018. Furthermore, differences between the predicted and actual readmission rates reflect how well Maryland performed relative to what was expected based on 2018. We specified two models: One adjusting for age groups, race, sex, dual eligibility status, and the 38 Elixhauser comorbidity flags, and another with just the Elixhauser comorbidity flags. While the results are similar, this report includes the simpler model that only contained the Elixhauser comorbidity flags so that it could focus on changes in health status over time. In addition, the analysis was run for all ages combined, and then for those under 65 versus those 65 and older; given the similarities in results, we have focused on the 65+ model since it is majority of the at-risk population for Medicare and this aligns with the national readmissions measures that restrict to those 65 and older.

The Figure 1 below shows the predicted readmission rate nationally and for Maryland increased by 2.95 and 4.74 percent respectively. The increase in the predicted readmission rate in Maryland indicates that the patients admitted to Maryland hospitals in 2022 were sicker than the patients admitted in 2018, and the increase in case mix index was higher in Maryland than it was nationally.

Figure 1. Predicted and Actual Maryland and National Readmissions

CCW Analysis		HSCRC Readmission Predictions for 65+ Yrs (CY Dec - Nov)				
Provider	Index Stay Year	Actual Admissions	Actual Readmissions	Predicted Readmission Rate	Actual Readmission Rate	Readmission Rate Difference
National	2018	6,866,364	976,561	14.22%	14.22%	0.00%
National	2019	6,786,204	967,802	14.40%	14.26%	-0.14%
National	2020	5,602,629	789,957	14.62%	14.10%	-0.52%
National	2021	5,354,330	758,226	14.62%	14.16%	-0.46%
National	2022	5,282,350	747,517	14.64%	14.15%	-0.49%
Change from 2018 to 2022				2.95%	-0.49%	
Maryland	2018	149,748	21,229	14.55%	14.18%	-0.38%
Maryland	2019	146,970	20,177	14.72%	13.73%	-0.99%
Maryland	2020	121,924	16,767	15.00%	13.75%	-1.25%
Maryland	2021	122,250	17,495	15.10%	14.31%	-0.79%
Maryland	2022	121,574	17,226	15.24%	14.17%	-1.07%
Change from 2018 to 2022				4.74%	-0.07%	
Prediction using 2018 national data as baseline						
Model is adjusted for 38 Elixhauser comorbidity flags (ICD-10 version)						


Figure 1 also shows the difference between the predicted and observed readmission rates. In CY 2022, Maryland had an actual readmission rate that was 1.07 percent lower than the predicted readmission rate, and this was more than twice as much as the gap between predicted and actual seen nationally (0.49 percent lower). Overall, staff contend that these analyses support the assertion that Maryland patients are sicker in 2022 than in 2018 and this increase in case mix severity is higher than what was seen nationally.

1) Per Capita Readmissions

Another approach to controlling for different admitting populations is to examine the number of readmissions per beneficiary rather than the readmission rate. This removes changes in the nature of the admitted population (the denominator in the traditional readmission rate) and focuses on just the number of readmissions across the entire population. Figure 2 compares Maryland's performance versus the Nation using readmissions per 1000 and the unadjusted CMMI readmission rate. Performance shows that in 2013 both the unadjusted and per capita readmission rates for Maryland were higher than the Nation by 7.9 percent and 9.9 percent, respectively. Starting in 2016 and 2017, the per capita and the unadjusted readmission rate dropped to below the national rate until 2021 where the unadjusted rate again is higher than the Nation but the per capita rate is below the Nation. And while there was erosion in 2021 Maryland,

in CY 2022 the per capita rate drops to 14.3 percent lower than the nation. This means that fewer Medicare beneficiaries are readmitted in Maryland than nationally and it aligns with the idea that those who are admitted in Maryland have a higher case mix acuity than the Nation and thus a higher unadjusted readmission rate.

Figure 2: Maryland's Performance Versus the Nation Under Unadjusted Readmission Rate and Readmissions per 1000¹⁵




2) Risk-Adjusted Medicare Readmission Rates

As discussed in the previous exemption request and above, reductions in inpatient utilization and differential COVID impacts, have increased the case mix index for patients admitted to the hospital in Maryland compared to the nation. Thus the staff continue to advocate for a risk-adjusted readmission measure and appreciate the CMMI team's agreement to collaborate with Maryland to develop a risk-adjusted readmission measure for consideration. By moving to a risk-adjusted measure, Maryland's performance on readmissions can be more fully evaluated since differences in the admitted population are removed. Currently, HSCRC staff has run regression models for Medicare beneficiaries who were 65 and older using the CCW data for 2013, 2020, 2021, and 2022 controlling for age, sex, COVID-19 status (for post-2020

¹⁵ HSCRC calculation based on 100% Maryland and National Hospital Claim files received annually.

models), Major Diagnostic Category (MDC) and the Elixhauser Comorbidity Index¹⁶. The results of these models show that in 2021 and 2022, despite higher unadjusted readmissions, Maryland patients had statistically significantly lower odds of being readmitted (2021 OR 0.97, CI 0.956-0.989; 2022 OR 0.95, CI 0.936-0.969). Figure 3 shows the odds ratios for each year. For CY 2022, the odds ratio of 0.95 means that Maryland Medicare FFS patients had a 5 percent lower odds of being readmitted than national patients. We then tested removing the Elixhauser Comorbidity Index for CY 2020, CY 2021, and CY 2022; for CY 2020 the OR increased to 0.972 but Maryland still performed statistically better than the Nation (CI 0.952-0.993) but for CY 2021 and CY 2022 the OR increased and there no longer was a statistically significant difference between MD and the nation. We believe this shows that during CY 2021 and again in CY 2022, MD admissions had higher comorbidities than national admissions (or 2020 admissions), which accounts for the higher unadjusted readmission rate. Again the HSCRC staff appreciate the collaboration with CMMI on developing a risk-adjusted readmission rate for comparing Maryland to the nation.

Figure 3: Odds Ratio for Risk-Adjusted Readmission Rates for Maryland vs. Nation



¹⁶ The Elixhauser Comorbidity Index has ICD-9 and ICD-10 versions with different comorbidity flags. Staff tested using the actual version that corresponded with the time period and using the comorbidity flags that were common across both versions. The results did not meaningfully differ, so the results presented here use the common flags.



maryland
health services
cost review commission

Workgroup Management Process

February 2024

Table of Contents

Background	1
Purpose & Staffing	1
Communications	1
Membership	1
Meetings	2

Background

The HSCRC is formalizing the below processes regarding preparing for workgroup meetings, managing communications and membership, and hosting and facilitating meetings in a public setting. HSCRC solicited public feedback on proposed workgroup management processes through January 31, 2024. Staff considered the feedback and have incorporated select recommendations into the processes outlined below. The Commission will review workgroup management workflows on a regular basis and revise them as needed.

Purpose & Staffing

1. The HSCRC will operate three standing workgroups: Payment Models, Performance Measurement, and Total Cost of Care.
2. Standing workgroups will have a written charge.
3. Technical subgroups will have written charges and report back to standing workgroups.
4. Each workgroup meeting will be led by HSCRC staff.
5. Workgroups are meant to support staff in advancing the mission of the HSCRC and are advisory bodies only.

Communications

1. Each workgroup will have its own webpage and email address.
2. Industry representatives and members of the public can email the dedicated email address to be added to workgroup distribution lists.
3. HSCRC staff will aim to issue workgroup materials in advance of meetings to give members sufficient time to review and prepare.
4. HSCRC will maintain a master calendar of standing workgroup and subgroup meeting dates on the HSCRC website.

Membership

1. The HSCRC strives toward diversity in expertise, experience, background, geography, and race/ethnicity in its workgroups.
2. Each workgroup will have listed membership which staff will review annually and determine if there is a need to replace any members.
3. Staff will monitor member attendance and consider attendance records during its annual review of membership rosters.
4. Staff will consider developing a dedicated consumer engagement approach.

Meetings

1. Each meeting will be open to the public.
2. All meetings will be announced and have materials and minutes or recordings posted on the website in a timely manner.
3. Workgroups may set aside time at meetings for public comment.
4. Each meeting will offer closed captioning to ensure meeting content is accessible to all participants and listeners.



January 31, 2024

Erin Shurmann
Chief, Provider Alignment and Special Projects
Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, MD 21215

Dear Ms. Shurmann,

Adventist HealthCare appreciates the opportunity to comment on the proposed Policy Development & Workgroup Process Updates. We strongly support the proposed changes as they are necessary for informed decision-making and transparency.

Workgroup Management

Adventist strongly supports the proposed changes for workgroup management. It's critical that standing workgroups have a written charge and a balanced membership to ensure diversity of expertise, geography, gender and race/ethnicity. Additional considerations include:

- **Balance of city, suburban and rural hospitals** as they represent diverse perspectives.
- **Representation from Prince George's and Montgomery counties as the two most populous counties in the state.** We have often observed heavy representation of Baltimore City interest on State workgroups. Prince George's and Montgomery counties are experiencing vastly different population challenges than Baltimore City and should have a clear voice at the table representative of their dominant populations.
- **Timely and consistent posting of materials.** Historically, meeting materials have not been consistently posted in advance of meetings or after meetings making it challenging to prepare meaningful feedback for workgroup meetings. Additionally, not all workgroup meeting materials have been posted to HSCRC's website and not all meetings have been recorded. With the large number of workgroup meetings, it's critical to post recordings of these public meetings so that stakeholders can stay up to speed. We look forward to more consistency with the proposed changes.



- **Reliable maintenance of HSCRC distribution lists.** Historically, inconsistent practices have been used to be added to distribution lists for meetings and materials. Multiple requests for addition to workgroup or memo distribution lists sometimes fail. A process should be put in place for stakeholders to sign up for workgroups and maintain key contact lists. Often, critical memos are sent to the wrong leaders. Adventist recognizes the difficult task of maintaining up-to-date contact lists for the State but encourages stronger processes and automation to maintain these critical communication channels.
- **Standing agenda time for public comment.** While several work groups already encourage public comment during meetings, this is not a consistent practice. To effectively engage stakeholders, a forum is needed to raise concerns that may be outside the pre-programmed agenda. Open comment periods to raise relevant concerns should be encouraged. Additionally, Adventist strongly supports the recommendation for stakeholder feedback on workgroups.
- **Adventist strongly supports the proposed 2-month period for draft policy and allowing comments during the presentation of the draft policy.** Often, the compressed time frame to provide feedback results in rushed feedback without the opportunity for thoughtful consideration. Given the impact of HSCRC payment policy on Marylander's access-to-care it's critical that adequate vetting time is allowed to discern potential inequities or inadequacies of a potential policy.
- **Clear posting of final payment policies.** The current HSCRC website is fractured to access final payment policies. Often it is faster to use Google to search for final memos or policies rather than navigate the HSCRC website. There are currently 25+ payment policies; it should be easy to quickly access the most current version. The current website does not facilitate this.
- **HSCRC should consider a master calendar to make it easy to see all scheduled meetings.** Currently, workgroup meetings are buried under individual web pages, and you have to know what to look for in order to find the appropriate meetings. A centralized calendar that lists all public meetings would make it easier for stakeholder to ensure appropriate engagement.

Thank you for considering our perspectives and contributions.



Katie Eckert, CPA
Vice President, Reimbursement & Strategic Analytics
Adventist HealthCare





MedStar Health

8094 Sandpiper Circle
Suite G
Nottingham, MD 21236

MedStarHealth.org

January 31, 2024

Joshua Sharfstein, MD
Chairman
Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, Maryland 21215

Dear Chairman Sharfstein,

On behalf of MedStar Health (MedStar) we appreciate the opportunity to comment on the Health Services Cost Review Commission's (HSCRC) proposed changes to the policy making process. MedStar strongly supports the changes proposed by the HSCRC to increase transparency, stakeholder participation, and public participation in the policy making process. MedStar echoes the points included in the Maryland Hospital Association's comment letter on this subject. Included in this letter are key points that MedStar is strongly in favor of and believes implementation of these changes would be beneficial to all stakeholders.

Distribute workgroup materials to the public one week prior to meetings and continue maintenance of workgroup information on HSCRC website.

MedStar applauds the collaborative nature of the HSCRC staff across the various workgroups convened to discuss and develop policy recommendations to be brought forward before the HSCRC. To ensure that stakeholders have adequate time to understand & formulate constructive feedback on policy proposals, MedStar strongly encourages the staff to commit to distributing meeting materials at least one week prior to meeting dates whenever possible. Additionally, maintaining the workgroup information regularly and providing frequent updates to the HSCRC website to ensure meeting materials are available after the fact is crucial to stakeholders being well informed as policies are developed and MedStar encourages that this practice is maintained.

Allow public comments on draft HSCRC staff recommendations and timely posting of final Commission decisions, inclusive of commissioner votes & adopted amendments.

To increase stakeholder engagement in the policy making process, MedStar strongly encourages that the HSCRC allow for oral comments to be made on draft staff recommendations brought before the HSCRC.

It's how we treat people.

Currently, only allowing oral comments to be made on final staff recommendations limits the ability of commissioners to hear from all interested parties prior to voting on policies. In addition, to provide clarity to the public, MedStar encourages the HSCRC to publish final approved policies on their website, including any approved amendments to staff recommendations, and the final commissioner voting records. This will help avoid any circumstances where the public is not clear on exactly what has been approved by the HSCRC, particularly when amendments are proposed and adopted to final policy recommendations.

Again, MedStar supports HSCRC leadership and staff in this endeavor to promote and increase transparency and stakeholder engagement in the policy making process. We hope that the additional changes suggested in this letter can be implemented to help further the goals of the HSCRC leadership and staff and looks forward to continuing to work in partnership during the development of healthcare payment policies in Maryland.

Sincerely,

A handwritten signature in black ink, appearing to read "Wood", written in a cursive style.

Mike Wood
Vice President, Revenue Management & Reimbursement
MedStar Health



Maryland
Hospital Association

January 31, 2024

Jon Kromm
Executive Director
Health Services Cost Review Commission
4160 Patterson Avenue
Baltimore, MD 21215

Dear Mr. Kromm,

On behalf of the Maryland Hospital Association's (MHA) member hospitals and health systems, we appreciate the opportunity to comment on Health Services Cost Review Commission (HSCRC) staff's recommendations on policymaking and work group processes.

We appreciate the Commission engaging stakeholders in the development process for informed decision making, transparency, inclusivity, and continuous evaluation. We look forward to collaborating with Commissioners and staff on the opportunities presented below.

Policy & Program Development

The hospital field is in general agreement with the draft policy and program development workflow with additional recommendations:

- Incorporate opportunities for stakeholder engagement and public feedback in the prioritization process. Commission priorities should be open for public comment, so stakeholders can provide feedback on those that are most impactful, operationally feasible, and contribute to Model success. Related to this suggestion, the priorities from the December Commissioner retreat should be presented for public comment at an upcoming meeting.
- Determine the criteria to develop new policies including an evaluation of ability to impact the stated outcomes and goals.
- Embed appropriate checkpoints throughout the policymaking process to ensure stakeholders can give meaningful feedback on methodological and operational considerations before policies are finalized.
- Leverage current best practices like the quality policy development calendar, shared with the Performance Measurement Work Group at each meeting.
- Participate in conversations with the hospital field and HSCRC with CMMI on Model administration to allow the field to offer insights on operational feasibility and how certain elements may be improved.

Promulgating Policies & Regulations (COMAR)

The hospital generally agrees with the draft workflows for promulgating workgroup vetted policies and regulations, particularly implementing longer time periods between presentation of draft policies to the Commission and final vote. We also put forth the following recommendations:

- Strongly encourage the reinstatement of oral comments on draft recommendations to allow commissioners to hear from all interested parties before final recommendations.
- Post final Commission decisions including commissioner votes, proposed, and adopted amendments, and final policies, as done currently for staff recommendations.
- Develop a process for refinement and evaluation of policies, considering the total impact of risk and rewards across policies to ensure incentives are balanced. Sunset unnecessary policies as needed to focus on those producing the most meaningful engagement and results.

Work Group Management

The hospital field is in general agreement with the draft recommendations, particularly identifying the scope and charge of each group. We also request the incorporation of the following:

- Strongly encourage longer time periods for stakeholders to vet policy and methodological recommendations prior to Commissioner vote to allow for evaluation of key issues and barriers, amendments where appropriate, and thoughtful evaluation and monitoring.
- Limit the number of new regulatory policies and methodologies to allow hospitals to develop and finalize methodologies and operationalize changes sequentially. This will limit competing priorities and allow for more meaningful engagement.
- Encourage more transparency in the workgroup management including posting all work group materials at least one week in advance of meetings, reviewing rosters annually, and distributing meeting summaries with clear and actionable next steps. If materials are not sent out with enough time to process (less than a week), we encourage meetings to be delayed for meaningful feedback.

Thank you for engaging stakeholders in the process. We believe our recommendation will further enhance the good work put forth in your draft document. If you want to discuss any of our recommendations in more detail, please contact us.

Sincerely,



Melony G. Griffith
President & CEO
Maryland Hospital Association

cc: Joshua Sharfstein, M.D., Chairman
Joseph Antos, Vice Chairman
James Elliott, M.D.
Ricardo Johnson
Maulik Joshi, DrPH
Adam Kane
Nicki McCann, JD



maryland
health services
cost review commission

Policy Calendar

Calendar Year 2024 through June 2025

Table of Contents

Introduction	1
Impact of AHEAD on HSCRC Activities	1
Anticipated Commission Votes (January 2024 – June 2025)	2
Policy Summaries	6
Quality	6
Rate Setting & Financial Methodologies	7
Healthcare Infrastructure Support	7
New and Ongoing Staff Activities	7
Appendix 1. HSCRC Staff Activities Timeline	8

Introduction

This document reflects staff and Commissioner discussion on priorities for the HSCRC over 18 months between January 2024 and June 2025. Staff is sharing a policy and activities calendar that staff believes is both ambitious but achievable given the current resources available to the HSCRC. Staff have considered current staff capacity and workload, existing contractor resources, state partner support, and future procurement requirements when developing this document. This document contains two components:

1. A list of HSCRC policies that will receive a Commission vote and a month-by-month outline of all policies that will be considered at each meeting through June 2025.
2. An outline of staff activities required to advance and implement the policies and programs critical to the State's all-payer rate setting system and the Maryland Model.

The activities outlined as part of #2 may be specific to implementing existing policies or programs, critical for hospital rate setting purposes, or required by the Center for Medicare and Medicaid Innovation (CMMI) under the terms of the Total Cost of Care (TCOC) Model State Agreement.

Impact of AHEAD on HSCRC Activities

The Centers for Medicare & Medicaid Services (CMS) released a Notice of Funding Opportunity (NOFO) for the States Advancing All-Payer Health Equity Approaches and Development (AHEAD) Model in fall 2023. The AHEAD Model is an 11 year, voluntary, state total cost of care model that seeks to drive state and regional health care transformation and multi-payer alignment to accelerate transformation across the entire health system. The AHEAD Model is designed to curb health care cost growth, improve population health, and advance health equity by reducing disparities in health outcomes across all payers including Medicare, Medicaid, and private coverage. AHEAD is the pathway to continue Maryland's all-payer rate setting authority and offers tools for primary care transformation, healthcare cost containment, and population health improvement. AHEAD builds on the Maryland TCOC Model, advancing the vision of equity and excellence in Maryland's healthcare delivery system to improve the health of all.

Maryland anticipates applying to participate in Cohort 1 of AHEAD which would run from CY 2026 through CY 2034. The Model would be preceded by an 18-month pre-implementation period (June 2024-December 2025) wherein the State and CMS would negotiate a State Agreement outlining the terms of Maryland's participation in AHEAD. The activities outlined in this document do not account for the level of effort and resources required of HSCRC staff to implement AHEAD, if Maryland is accepted into the model.

Anticipated Commission Votes (January 2024 – June 2025)

Based on discussion of existing policy requirements, policy refinement opportunities, and implementation responsibilities, staff have developed the following calendar for updating and developing new policies between CY 2024 and June 2025. Dates are subject to change based on staff capacity, data availability, stakeholder input, and other factors that may delay the policy-making process. Staff aim to have a two-month gap between presenting a draft policy recommendation and a Commission vote on a final policy recommendation (e.g. a draft is presented in March and a final is presented in May) if a policy is being developed for the first time or substantive changes are being made. This revised timeline may not be possible for select policies where data limitations, compliance requirements, and other time-sensitive issues impact the development timeline. In those cases, a final policy recommendation will be presented in the subsequent month following a draft.

In advance of submitting draft recommendations, staff will bring proposed policy development plans to Commissioners for consideration on a quarterly basis. Policy development plans will include goals, a plan for needed data and analytics, a plan for stakeholder engagement, and an anticipated timeline. Staff plan to provide these quarterly updates in the following months:

- April 2024
- July 2024
- October 2024
- January 2025
- April 2025

Staff are providing the below table outlining the policies that the Commission will vote on between January 2024 and June 2025. **The dates listed may change and any changes will be reflected in the monthly Commission meeting agendas posted on the HSCRC website.** Many 2024 policies in development are nearing completion, so staff will begin presenting development plans for fall policies in Spring/Summer 2024.

Table 1. CY 2024 Policy Votes

CY 2024 Policy Votes	Development Plan	Draft Policy	Final Policy Vote
Multi-Visit Patient Policy (RY 2026)		December 2023	February 2024

CY 2024 Policy Votes	Development Plan	Draft Policy	Final Policy Vote
Medicare Performance Adjustment (CY 2024 Policy / FY 2026 Payment)		December 2023	February 2024
Readmission Reduction Incentive Program (RRIP – RY 2026)		February 2024	April 2024
Relative Value Unit (RVU) Updates (FY 2025)		April 2024	June 2024
Nurse Support Program II – Competitive Grants (FY 2025)			May 2024
Update Factor (RY 2025)		May 2024	June 2024
CRISP HIE Funding (RY 2025)		May 2024	June 2024
Out-of-State (OOS) and Deregulation Volume Policy	April 2024	July 2024	September 2024
ED Best Practices Incentives	March 2024	October 2024	December 2024
Quality Based Reimbursement (QBR) Program (RY 2027)	July 2024	October 2024	December 2024

Table 2. CY 2025 Policy Votes

CY 2025 Policy Votes	Development Plan	Draft Policy	Final Policy Vote
Maryland Hospital Acquired Condition (MHAC) Program (RY 2027)	July 2024	November 2024	January 2025
Nurse Support Program II – Program Renewal (FY 2026 – 2023)	April 2024	November 2024	January 2025
Medicare Performance Adjustment (CY 2025 Policy / FY 2027 Payment)	October 2024	December 2024	February 2025
Revenue for Reform (RY 2026)	July 2024	December 2024	February 2025
Multi-Visit Patient Policy (RY 2027)	July 2024	December 2024	February 2025

CY 2025 Policy Votes	Development Plan	Draft Policy	Final Policy Vote
Freestanding Medical Facility (FMF) Conversion Policy	July 2024	January 2025	March 2025
Readmission Reduction Incentive Program (RRIP – RY 2027)	July 2024	February 2025	April 2025
Relative Value Unit (RVU) Updates (FY 2026)	January 2025	April 2025	June 2025
Nurse Support Program II – Competitive Grants (FY 2026)	July 2024		May 2025
Update Factor (RY 2026)	January 2025	May 2025	June 2025
CRISP HIE Funding (RY 2026)		May 2025	June 2025

Table 3. CY 2024 Presentations by Month

Month	Policy & Presentation Type
February 2024	<ol style="list-style-type: none"> Final Policy – Multi-Visit Patient Policy (RY 2026) Final Policy - Medicare Performance Adjustment (CY 2025 Policy / FY 2027 Payment) Draft Policy – Readmissions Reduction Incentive Program (RY 2026)
March 2024	<ol style="list-style-type: none"> Development Plan - ED Best Practices Incentive Policy
April 2024 (Quarterly Update)	<ol style="list-style-type: none"> Draft Policy - Relative Value Unit Updates (FY 2025) Development Plan – Nurse Support Program II Program Renewal (FY 2026 – 2030) Development Plan – OOS and Deregulation Policy
May 2024	<ol style="list-style-type: none"> Final Policy – Nurse Support Program II – Competitive Grants (FY 2025) Draft Policy – Update Factor (RY 2025) Draft Policy – CRISP HIE Funding (RY 2025)
June 2024	<ol style="list-style-type: none"> Final Policy – Update Factor (RY 2025) Final Policy – CRISP HIE Funding (RY 2025) Final Policy – Relative Value Unit (RVU) Updates (FY 2025)

Month	Policy & Presentation Type
July 2024 (Quarterly Update)	<ol style="list-style-type: none"> 1. Draft Policy – OOS and Deregulation Volume Policy 2. Development Plan – Quality Program Updates (MHAC, QBR, RRIP) (RY 2027) 3. Development Plan – Revenue for Reform Policy Updates (RY 2026) 4. Development Plan – Multi-Visit Patient (MVP) Policy Updates (RY 2027) 5. Development Plan – Nurse Support Program II Competitive Grants (RY 2026) 6. Development Plan – FMF Conversion Incentive Program
September 2024	<ol style="list-style-type: none"> 1. Final Policy – OOS and Deregulation Policy
October 2024 (Quarterly Update)	<ol style="list-style-type: none"> 1. Draft Policy – Quality Based Reimbursement (QBR) Program Updates (RY 2027) 2. Draft Policy – ED Best Practices Incentive Policy 3. Development Plan – Medicare Performance Adjustment (CY 2025 Policy / FY 2027 Payment)
November 2024	<ol style="list-style-type: none"> 1. Final Policy - Quality Based Reimbursement (QBR) Program Updates (RY 2027) 2. Draft Policy – Nurse Support Program II Program Renewal (FY 2026 – 2030) 3. Draft Policy - Maryland Hospital Acquired Conditions (MHAC) Program Updates (RY 2027)
December 2024	<ol style="list-style-type: none"> 1. Final Policy - Maryland Hospital Acquired Conditions (MHAC) Program Updates (RY 2027) 2. Final Policy – ED Best Practices Incentive Policy 3. Draft Policy - Medicare Performance Adjustment (CY 2025 Policy / FY 2027 Payment) 4. Draft Policy - Revenue for Reform Policy Updates (RY 2026) 5. Draft Policy- Multi-Visit Patient (MVP) Policy Updates (RY 2027)

Table 4. CY 2025 Presentations by Month

Month	Presentation Type
January 2025 (Quarterly Update)	<ol style="list-style-type: none"> 1. Final Policy - Nurse Support Program II Program Renewal (FY 2026 – 2030) 2. Draft Policy - FMF Conversion Incentive Program 3. Development Plan – Relative Value Unit (RVU) Updates (FY 2026) 4. Development Plan – Update Factor (RY 2026)
February 2025	<ol style="list-style-type: none"> 1. Final Policy - Medicare Performance Adjustment (CY 2025 Policy / FY 2027 Payment) 2. Final Policy - Revenue for Reform Policy Updates (RY 2026) 3. Final Policy- Multi-Visit Patient (MVP) Policy Updates (RY 2027) 4. Draft Policy – Readmission Reduction Incentive Program (RRIP) (RY 2027)

Month	Presentation Type
March 2025	1. Final Policy - FMF Conversion Incentive Program
April 2025 (Quarterly Update)	1. Final Policy - Readmission Reduction Incentive Program (RRIP) (RY 2027) 2. Draft Policy - Relative Value Unit (RVU) Updates (FY 2026)
May 2025	1. Final Policy – Nurse Support Program II Competitive Grants (FY 2026) 2. Draft Policy – Update Factor (RY 2026) 3. Draft Policy – CRISP HIE Funding (FY 2026)
June 2025	1. Final Policy – Update Factor (RY 2026) 2. Final Policy – CRISP HIE Funding (RY 2026)

Policy Summaries

Below are high level summaries of the policies that the Commission will consider in CY 2024 and the first half of CY 2025.

Quality

- Quality-Based Reimbursement Program:** Ensures quality of hospital care across multiple domains; comply with TCOC Model contractual obligation to meet or exceed the quality and cost outcomes of the Medicare Value Based Purchasing (VBP) program, and provide payment incentives to address/support state-specific priorities and goals through innovations in measurement areas and incentive design.
- Maryland Hospital Acquired Conditions (MHAC) Program:** Incentivizes maintaining prior reductions in hospital acquired complications in line with federal contractual obligation that requires the State to not backslide from All-Payer Model performance.
- Readmissions Reduction Incentive Program (RRIP):** Incentivizes reducing all-payer readmissions in line with federal contractual obligation that requires the State to have a Medicare readmission at or below the national average. Advances health equity through disparity gap methodology.
- Emergency Department (ED) Best Practices Incentive Policy:** Incentivizes hospital best practices, alignment with Emergency Department Dramatic Improvement Initiative (EDDIE), and value-based arrangements with non-hospital providers that will improve hospital throughput and by extension reduce ED length of stay (LOS).

- **Multi-Visit Patient (MVP) Policy:** Provides all-payer incentives for hospitals to develop alternative care pathways for the most frequent emergency department (ED) visitors.

Rate Setting & Financial Methodologies

- **Update Factor:** Provides hospitals with reasonable changes to rates in order to maintain operational readiness while also seeking to contain the growth of hospital costs in the State. In addition, the policy aims to be fair and reasonable for hospitals and payers. RY 2025 policy will include an update on the high-cost drug policy.
- **Medicare Performance Adjustment (MPA):** Brings direct financial accountability to individual hospitals based on the TCOC of Medicare fee-for-service (FFS) beneficiaries attributed to them.
- **Relative Value Unit (RVU) Updates:** Proposes updates to RVUs, which are values/weights assigned to a specific service based on relative resources used when compared to other services.
- **Revenue for Reform Policy:** Directs inefficient hospitals, which may be a function of retained revenue, to fund community-based population health investments outside of hospital walls.
- **Freestanding Medical Facility (FMF) Conversion Incentive Policy:** Establishes requirements for any major facility conversion (e.g., acute hospital to FMF). Outlines the process that hospitals will need to follow when considering a facility conversion and will establish the expected savings, maintenance of effort for various types of access and potential funding for population health.
- **Out-of-State (OOS) and Deregulation Volume Policy:** Ensure changes in hospital volumes for out-of-state volume growth and deregulation are appropriately captured in hospital global budgets.

Healthcare Infrastructure Support

- **CRISP Health Information Exchange (HIE) Funding:** Approves the annual assessment in hospital rates to fund and sustain projects and operations for CRISP, the State's HIE.
- **Nurse Support Program (NSP) II:** Administers special funding to advance nursing in higher education settings. The program is administered by the Maryland Higher Education Commission (MHEC). The Commission will vote on both the annual competitive grant awards and a five-year program renewal.

New and Ongoing Staff Activities

In addition to the policies that will be refined or newly developed over the next 18 months, HSCRC staff will continue to advance and implement the policies and programs critical to the State's all-payer rate setting system and the Maryland Model. The activities outlined may be specific to implementing existing policies or programs, critical for hospital rate setting purposes, or required by the Center for Medicare and Medicaid Innovation (CMMI) under the terms of the Total Cost of Care (TCOC) Model State Agreement.









Staff have grouped work into seven different categories:





- Financial Methodologies & Rate Setting
- Quality
- Population Health
- Care Transformation
- Data Management
- Hospital and Model Performance Monitoring
- State Health Infrastructure




Appendix 1 provides a work breakdown structure and timeline for staff activities through June 2025. A commission vote may or may not be required for staff to carry out the functions associated with the work outlined. Additionally, the list will be modified and updated as the year progresses. **Stakeholders should use these dates as a guide to HSCRC activities but refer to staff leading associated work for exact timelines, deadlines, and detailed workflows.** These timelines are subject to change if new policy needs emerge, staff determine that refinements are needed to existing policies or programs or competing priorities (such as AHEAD) require staff to redirect efforts.




Appendix 1. HSCRC Staff Activities Timeline

Policy Calendar (Financial Methodologies & Rate Setting) 🗨

▼ Update Factor (0%)	1/3/24	12/31/25
▼ FY 2025 (0%)	1/3/24	12/31/24
0% Staff development / Payment Models Workgroup	1/3/24	6/4/24
 Draft recommendation		5/8/24
0% Additional public comment	5/1/24	5/15/24
 Final recommendation		6/14/24
0% Rate order compliance / model monitoring	7/1/24	12/31/24
▼ FY 2026 (0%)	1/8/25	12/31/25
 Staff present development plan		1/8/25
0% Staff development / Payment Models workgroup	1/9/25	6/10/25
 Draft recommendation		5/14/25
0% Additional public comment	5/7/25	5/21/25
 Final recommendation		6/11/25
0% Rate order compliance / model monitoring	7/1/25	12/31/25
▼ Medicare Performance Adjustment (0%)	7/10/24	2/12/25
▼ CY 2025 (FY 27 Payment) (0%)	7/10/24	2/12/25
 Staff present development plan		7/10/24
0% Staff implement development plan	9/1/24	12/10/24
 Draft recommendation		12/11/24
0% Additional public comment / CMMI review	12/12/24	1/15/25
 Final recommendation		2/12/25
▼ Relative Value Unit (RVU) Updates (0%)	1/1/24	7/31/25
▼ FY 2025 Updates (0%)	1/1/24	7/31/24
0% Stakeholder engagement	1/1/24	3/31/24

	Draft recommendation		4/10/24
0%	Additional public comment	4/11/24	5/31/24
	Final recommendation		6/12/24
0%	Implement in rate orders	7/1/24	7/31/24
▼ FY 2026 Updates (0%)		1/1/25	7/31/25
0%	Stakeholder engagement	1/1/25	3/31/25
	Draft recommendation		4/9/25
0%	Additional public comment	4/10/25	5/31/25
	Final recommendation		6/11/25
0%	Implement in rate orders	7/1/25	7/31/25

▼ FMF Conversion / Facility Closure Policy (0%)		7/10/24	3/12/25
	Staff present development plan		7/10/24
0%	Staff development / stakeholder engagement / efficiency subgroup	7/11/24	12/31/24
	Staff present draft recommendation		1/8/25
0%	Additional public comment	1/9/25	2/14/25
	Staff present final recommendation		3/12/25



▼ OOS & Deregulation Volume Policy Development (0%)		2/1/24	9/11/24
0%	Staff planning	Yesterday	4/9/24
	Staff present development plan		4/10/24
0%	Staff development / stakeholder engagement / volume subgroup	4/11/24	6/30/24
	Staff present draft recommendation		7/10/24
0%	Additional public comment	7/11/24	8/16/24
	Staff present final recommendation		9/11/24

▼ Deregulation Adjustments (0%)		5/1/24	7/31/25
--	--	--------	---------

▼ FY 2024 (0%)	5/1/24	7/31/24
0% Final deregulation determinations	5/1/24	6/28/24
0% Implement deregulation activity	7/1/24	7/31/24
▼ FY 2025 (0%)	11/1/24	7/31/25
0% Final re regulation determinations	11/1/24	12/31/24
0% Implement deregulation activity	1/1/25	1/31/25
0% Final deregulation determinations	5/1/25	6/30/25
0% Implement deregulation activity	7/1/25	7/31/25
▼ Volume Policy Implementation (0%)	3/1/24	7/31/25
▼ Market Shift (0%)	4/1/24	7/31/25
▼ CY 2023 Market Shift (0%)	4/1/24	7/31/24
0% Run CY 2023 market shift	4/1/24	4/30/24
0% QC with industry	5/1/24	6/28/24
0% Implement in rate orders	7/1/24	7/31/24
▼ CY 2024 (6 mo) Market Shift (0%)	10/1/24	1/31/25
0% Run CY 2024 (6 mo) market shift	10/1/24	10/31/24
0% Implement in rate orders	1/1/25	1/31/25
0% QC with industry	11/1/24	12/31/24
▼ CY 2024 (Full) Market Shift (0%)	4/1/25	7/31/25
0% Run CY 2024 market shift	4/1/25	4/30/25
0% QC with industry	6/30/25	6/30/25
0% Implement in rate orders	7/1/25	7/31/25
▼ Demographic Adjustment (0%)	4/1/24	7/31/25
▼ RY 2025 Demographic Adjustment (0%)	4/1/24	7/31/24
0% Run DA for RY 2025 rate orders	4/1/24	4/30/24
0% QC demographic adjustment with industry	5/1/24	6/30/24
0% Implement in rate orders	7/1/24	7/31/24
▼ RY 2026 Demographic Adjustment (0%)	4/1/25	7/31/25
0% Run DA for RY 2025 rate orders	4/1/25	4/30/25

0%	QC demographic adjustment with industry	5/1/25	6/30/25
0%	Implement in rate orders	7/1/25	7/31/25
▼ Integrated Efficiency Policy (0%)		3/1/24	7/31/25
▼ FY 2025 (0%)		3/1/24	7/31/24
0%	Update ICC and TCOC calculations	3/1/24	3/29/24
0%	QC with industry	4/1/24	5/31/24
0%	Values reflected in UF	6/1/24	6/12/24
0%	Implement in rate orders	7/1/24	7/31/24
▼ FY 2026 (0%)		3/1/25	7/31/25
0%	Update ICC and TCOC calculations	3/1/25	3/1/25
0%	QC with industry	4/1/25	5/30/25
0%	Values reflected in UF	6/1/25	6/11/25
0%	Implement in rate orders	7/1/25	7/31/25
▼ OOS Adjustments (0%)		8/1/24	1/31/25
0%	Run OOS adjustments	8/1/24	8/30/24
0%	Implement in rate orders	1/1/25	1/31/25
▼ ECMAD Weight Updates (0%)		1/1/24	4/30/24
0%	Complete staff development	1/1/24	1/31/24
0%	Release updated weight to industry	Yesterday	2/29/24
0%	Use in ICC	3/1/24	3/29/24
0%	Use in market shift / demographic adjustment	4/1/24	4/30/24
▼ Full Rate Application Policy (0%)		3/1/24	7/31/25
▼ FY 2025 (0%)		3/1/24	7/31/24
0%	Update ICC and TCOC calculations	3/1/24	3/29/24
0%	QC with industry	4/1/24	5/31/24
0%	Values reflected in UF	6/1/24	6/12/24
0%	Implement in rate orders	7/1/24	7/31/24

▼ FY 2026 (0%)		3/1/25	7/31/25
0%	Update ICC and TCOC calculations	3/1/25	3/1/25
0%	QC with industry	4/1/25	5/30/25
0%	Values reflected in UF	6/1/25	6/11/25
0%	Implement in rate orders	7/1/25	7/31/25

▼ Uncompensated Care Policy (0%)		4/1/24	6/11/25
0%	Staff draft FY 2025 report	4/1/24	5/31/24
	Report on FY 2025 UCC pool presented to Commission		6/12/24
0%	Staff draft FY 2026 report	4/1/25	5/31/25
	Report on FY 2026 UCC pool presented to Commission		6/11/25

▼ Benchmarking (0%)		3/1/24	8/30/24
0%	Staff development / stakeholder engagement	3/1/24	4/30/24
0%	Implement revised benchmarking process for CY 2023 data	5/1/24	8/30/24

▼ Rate Order Issuance & Compliance (0%)		1/1/24	6/30/25
▼ RY 2024 Rates (0%)		1/1/24	6/30/24
0%	Rate order compliance monitoring	1/1/24	6/30/24
▼ RY 2025 Rates (0%)		7/1/24	6/30/25
0%	RY 2025 rate orders issued	7/1/24	9/30/24
0%	Rate order compliance	10/1/24	12/31/24
0%	Mid-year rate year orders issued, apply compliance penalties	1/1/25	1/31/25
0%	Rate order compliance monitoring	1/1/25	6/30/25






▼ ARMs / Docketing (0%)		1/1/24	6/30/25
0%	Monthly reviews & approvals	1/1/24	6/30/25
▼ Hospital Specific Requests/ Negotation & Implementation (0%)		1/1/24	6/30/25
0%	Ongoing negotiations & implementation activities	1/1/24	6/30/25


Policy Calendar (Quality) - CY 2024 🗨

▼ QBR Policy (1%)	1/1/24	11/13/24
▼ RY 2026 (100%)	1/1/24	1/1/24
◇ RY 2026 Performance Period begins (Oct for CMS measures)		1/1/24
▼ RY 2027 (0%)	7/10/24	11/13/24
◇ Staff present Quality Programs development plan		7/10/24
0% Staff development / stakeholder engagement	7/11/24	10/8/24
◇ Staff present draft policy		10/9/24
0% Additional public comment	10/2/24	10/16/24
◇ Staff present final recommendation		11/13/24






▼ MHAC Policy (1%)	1/1/24	1/1/25
▼ RY 2026 (100%)	1/1/24	1/1/24
◇ RY 2026 Performance Period begins		1/1/24
▼ RY 2027 (0%)	7/10/24	1/1/25
◇ Staff present Quality Programs development plan		7/10/24
0% Staff development / stakeholder engagement	7/11/24	11/12/24
◇ Staff present draft policy		11/13/24
0% Additional public comment	11/6/24	11/20/24
◇ Staff present final recommendation		12/11/24
◇ RY 2027 Performance Period begins		1/1/25

▼ RRIP (1%)	1/1/24	3/12/25
▼ RY 2026 (7%)	1/1/24	3/13/24
◇ RY 2026 Performance Period begins		1/1/24
◇ Staff present draft recommendation		2/14/24
0% Additional public comment	Wednesday	2/21/24

	Staff present final recommendation		3/13/24
▼ RY 2027 (0%)		7/10/24	3/12/25
	Staff present Quality Programs development plan		7/10/24
0%	Staff development / stakeholder engagement	11/1/24	2/11/25
	Staff present draft policy		2/12/25
0%	Additional public comment	2/5/25	2/19/25
	Staff present final recommendation		3/12/25
	RY 2027 Performance Period begins		1/1/25

▼ Population Health - IP Diabetes Screening Measure (0%)		2/1/24	9/15/24
0%	Data Collection	Yesterday	9/15/24
	Pilot Program begins		7/1/24

▼ Population Health - MPA Measure (100%)		1/1/24	1/31/24
100%	Develop PQI incentive for MPA recommendation	1/1/24	1/31/24

▼ Multi-Visit Patient Policy (1%)		1/1/24	2/12/25
▼ RY 2026 (50%)		1/1/24	2/14/24
	RY 2026 Performance Period begins		1/1/24
	Staff present final recommendation		2/14/24
▼ RY 2027 (0%)		7/10/24	2/12/25
	Staff present Quality Program development plan		7/10/24
0%	Staff development / stakeholder engagement	8/1/24	12/10/24
	Staff present draft recommendation		12/11/24
0%	Additional public comment	12/12/24	2/11/25
	Staff present final recommendation		2/12/25

▼ Emergency Department Initiatives (0%)	1/1/24	6/30/25
▼ ED Best Practices Initiatives (0%)	3/13/24	3/13/24
◊ Staff present development plan		3/13/24
▼ EDDIE (0%)	1/1/24	6/30/25
0% Ongoing monthly data collection, analysis, and reporting	1/1/24	6/30/25

▼ Digital Measure Development (0%)	1/1/24	2/28/25
▼ CY 2025 Measure (0%)	1/1/24	2/29/24
0% Staff development / stakeholder engagement	1/1/24	1/31/24
0% Final measure selection for CY 2025	Yesterday	2/29/24
▼ CY 2026 Measure (0%)	12/1/24	2/28/25
0% Staff development / stakeholder engagement	12/1/24	1/31/25
0% Final measure selection for RY 2028	2/1/25	2/28/25





▼ Health Equity Measure Development (0%)	1/1/24	6/30/25
0% Continue reporting and evaluation of existing disparity gap measures	1/1/24	6/30/25
0% Continue analysis of disparities in current quality and population health measures	1/1/24	6/30/25

▼ Value-Based Program (VBP) Exemption Request (0%)	4/1/24	6/28/24
0% Staff draft exemption request	4/1/24	6/27/24
◊ Exemption request submitted to CMMI		6/28/24

▼ Hospital Reporting - Quality Programs (0%)	1/1/24	6/30/25
0% Memos and educational resources on policy updates	1/1/24	6/30/25

0%	Annual grouper updates and report development	10/1/24	3/31/25
0%	Monthly reporting to hospitals on all quality policies	1/1/24	6/30/25
0%	Technical support for hospitals and other stakeholders	1/1/24	6/30/25

Policy Calendar (Pop Health) - CY 2024 🗨

▼ Revenue for Reform (0%)	2/1/24	6/30/25
▼ FY 2024 Implementation (0%)	4/8/24	9/30/24
0% Measurement/outcomes discussions	4/8/24	4/30/24
0% Performance reporting	6/3/24	9/30/24
▼ FY 2025 Updates (0%)	2/26/24	6/28/24
0% Application updated and released	2/26/24	3/8/24
0% Hospitals work on applications / TA with HSCRC & MDH	3/11/24	5/10/24
0% MDH & HSCRC review applications	5/13/24	5/31/24
0% Hospital meetings / revisions / approvals	6/1/24	6/28/24
▼ FY 2026 - Development (0%)	2/1/24	2/28/25
0% Draft development plan	Yesterday	4/9/24
 Present development plan to Commission		4/10/24
0% Staff development - MDH collaboration, analytics, stakeholder engagement	4/11/24	7/9/24
 Present draft policy recommendation		12/11/24
0% Collect & review stakeholder content	7/11/24	9/10/24
 Present final recommendation		2/12/25
0% Update FY 2026 application	2/13/25	2/28/25
▼ FY 2026 Implementation (0%)	2/13/25	6/30/25
0% Application updated and released	2/13/25	2/28/25
0% Hospitals work on applications / TA with HSCRC & MDH	3/1/25	5/15/25
0% MDH & HSCRC review applications	5/16/25	5/30/25
0% Hospital meetings / revisions / approvals	6/1/25	6/30/25
▼ Community Benefits (0%)	1/1/24	1/30/25
▼ FY 2023 Reporting (0%)	1/1/24	9/11/24
0% Hospital data due	1/1/24	1/31/24
0% Staff / Hilltop develop FY 2023 report	Yesterday	8/30/24
		

Staff release report to Commission / public		9/11/24
▼ FY 2024 Reporting (0%)	1/1/25	1/30/25
0% Hospital data due	1/1/25	1/30/25
▼ FY 2025 Reporting (0%)	4/1/24	5/31/24
0% Stakeholder engagement w hospitals on FY25 instruction changes	4/1/24	5/31/24



▼ Regional Partnership Catalyst Program (0%)	2/28/24	6/30/25
▼ Diabetes Funding (0%)	2/28/24	6/30/25
◇ RP wind-down budgets & high-level plans due		2/28/24
◇ CY 2023 annual reports due		5/1/24
0% Staff review annual reports & draft annual report	5/2/24	8/30/24
◇ Staff present annual CY 2023 report		9/11/24
0% Staff receive mid-year updates on wind-down activities	6/1/24	8/30/24
◇ CY 2024 (Final Year) reports due		3/15/25
0% Staff review annual reports / draft final summary report	3/16/25	6/30/25
▼ Behavioral Health Funding (0%)	3/15/24	9/11/24
◇ CY 2023 annual reports due		3/15/24
0% Staff review annual reports & draft annual report	3/17/24	5/31/24
0% Staff draft behavioral health content for annual report	6/3/24	7/31/24
◇ Staff present annual report		9/11/24
▼ Maternal & Child Health Improvement Initiative (MDH & Medicaid) (0%)	12/1/24	12/1/24
◇ MDH submits annual report on FY 2024 activities		12/1/24

▼ Innovation Fund (0%)	1/31/24	6/28/24
0% Staff concept development	1/31/24	6/28/24

Policy Calendar (Care Transformation) - CY 2024 🗨

▼ Episode Quality Improvement Program (0%)	1/1/24	12/31/26
▼ CY 2025 Performance (0%)	1/1/24	1/1/25
0% Evaluation & new episode design	1/1/24	4/30/24
0% EQIP Enrollment	7/1/24	12/31/24
📅 Performance Year Begins		1/1/25
▼ CY 2026 Performance (0%)	1/1/25	12/31/26
📅 0% Evaluation & new episode design	1/1/25	4/30/25
0% EQIP Enrollment	7/1/25	12/31/26
📅 Performance Year Begins		1/1/26
▼ EQIP - Primary Care (2%)	1/26/24	1/1/25
📅 RFI Responses Due		1/26/24
📅 Staff present report on program plan		4/10/24
0% CMMI review	4/8/24	5/8/24
0% Applications open	5/15/24	6/14/24
📅 Performance Year Begins		1/1/25
▼ Care Transformation Initiatives (0%)	12/1/23	7/1/24
▼ FY2025 Performance (0%)	12/1/23	7/1/24
0% New CTIs completed	3/1/24	3/29/24
0% Evaluation and design	12/1/23	2/29/24
📅 PY Begins		7/1/24
▼ FY2026 Performance (0%)	12/1/23	7/1/24
0% New CTIs completed	3/1/24	3/29/24
0% Evaluation and design	12/1/23	2/29/24
📅 PY Begins		7/1/24



Policy Calendar (Data Management) 


▼ Internal Retention & Destruction Policy (0%)		1/1/24	7/31/24
0%	Complete draft policy and criteria	1/1/24	1/31/24
0%	Implement policy changes across HSCRC	Yesterday	7/31/24
▼ Annual Updates to Case Mix Data Submission Requirements (0%)		3/1/24	7/1/24
0%	Stakeholder engagement for annual changes	3/1/24	6/30/24
	Updates go live		7/1/24
▼ Overhaul of Public Use Files (PUF) (0%)		1/1/24	7/31/24
0%	Stakeholder engagement	1/1/24	3/31/24
0%	Finalize policy	4/1/24	5/31/24
0%	Implement policy	7/1/24	7/31/24
▼ Hospital Auditing (0%)		1/1/24	7/1/24
▼ Casemix Audits (0%)		1/1/24	7/1/24
0%	Procurement process	1/1/24	5/31/24
	Contractor starts		7/1/24
▼ Monthly Data Collection - Financial & Casemix (0%)		1/1/24	6/30/25
0%	Ongoing financial and casemix data collection	1/1/24	6/30/25

Policy Calendar (Hospital & Model Compliance) 🗨

▼ Annual Filing Modernization (1%)	1/1/24	11/25/25
📦 Update to Commission		1/10/24
▼ Updates to Current Reporting (0%)	1/1/24	7/1/25
0% Feasibility surveys	1/1/24	3/29/24
0% Workgroups	Yesterday	5/31/24
0% Spring/Summer '24 Release	6/3/24	9/2/24
0% Updates complete	12/2/24	3/3/25
0% Full roll-out	6/2/25	7/1/25
▼ Data Management Updates (0%)	10/27/25	11/25/25
0% Developing web-based tool to use for future annual filings- TBD		
0% New tool goes live	10/27/25	11/25/25
▼ Accounting and Budget Manual Overhaul (0%)	1/26/24	9/24/25
▼ Phase I revisions (0%)	1/26/24	11/22/24
0% Phase I revisions	1/26/24	6/27/24
0% Phase 1 QC & Approval	6/27/24	11/22/24
0% Website development	1/26/24	7/25/24
▼ Phase II Revisions (0%)	1/27/25	9/24/25
0% Phase 2 Revisions	1/27/25	4/25/25
0% Phase 2 QC & Approval	4/28/25	7/28/25
0% Final publish online	8/26/25	9/24/25
▼ Model Performance Verification Development (0%)	4/1/24	7/31/25
▼ CY 2023 Performance (0%)	4/1/24	7/31/24
0% HSCRC compiles performance verification data for CMMI	4/1/24	5/15/24
0% CMMI reviews performance data	5/16/24	7/15/24
0% CMMI issues performance verification memo	7/16/24	7/31/24
▼ CY 2024 Performance (0%)	4/1/25	7/31/25
0%		

	HSCRC compiles performance verification data for CMMI	4/1/25	5/15/25
0%	CMMI reviews performance data	5/16/25	7/15/25
0%	CMMI issues performance verification memo	7/16/25	7/31/25

▼ Hospital Financial Condition Report (1%)		10/30/23	5/31/24
	Hospitals submit FY 2023 audited data		10/30/23
0%	Staff review data and draft report	11/1/23	5/30/24
	Report released		5/31/24

▼ Annual Legislative Report (0%)		2/1/24	5/1/24
0%	Staff draft report	Yesterday	Yesterday
	Staff submit report to legislature & Governor's office		5/1/24

▼ CMS Annual Monitoring Reports (0%)		4/1/24	1/31/25
0%	Expenditures Performance	4/1/24	7/31/24
0%	Outcomes-Based Credits	10/1/24	12/31/24
0%	Quality / Statewide Integrated Health Improvement Strategy	9/1/24	1/31/25

Policy Calendar (State Health Infrastructure) - CY 2024 🗨

▼ Nurse Support Program I (10%)	1/1/24	7/1/25
▼ FY 2023 Implementation (25%)	1/1/24	5/8/24
0% Staff review data & draft summary report	Yesterday	5/7/24
◇ Staff present report to Commissioners		5/8/24
▼ FY 2024 Implementation (0%)	1/1/25	5/14/25
0% Hospital data due	1/1/25	1/31/25
0% Staff draft report	2/3/25	5/9/25
◇ Staff present report to Commissioners		5/14/25
▼ FY 2025 Implementation (0%)	5/15/24	7/1/25
◇ Hospitals submit programs for approval		5/15/24
0% HSCRC reviews submissions	5/16/24	6/28/24
◇ FY 2025 performance period begins		7/1/25

▼ Nurse Support Program II (0%)	1/15/24	5/14/25
▼ Competitive Grants (0%)	1/15/24	5/14/25
▼ CG - FY 2025 (0%)	1/15/24	5/8/24
0% MHEC Application Period & Review	1/15/24	4/26/24
◇ Final Recommendation		5/8/24
▼ CG - FY 2026 (0%)	1/15/25	5/14/25
0% MHEC application period & review	1/15/25	4/30/25
◇ Final recommendation		5/14/25
▼ Program Renewal (0%)	2/1/24	12/11/24
0% Staff draft development plan	Yesterday	4/5/24
◇ Staff present development plan to Commission		4/10/24
0% Implement program renewal development plan	4/11/24	10/31/24
◇ Draft recommendation		10/9/24
0% Public comment reviewed	10/10/24	11/29/24
◇		

Final recommendation		12/11/24
▼ CRISP HIE Funding (0%)	3/1/24	6/11/25
▼ FY 2025 Funding (0%)	3/1/24	6/12/24
0% Develop funding recommendation	3/1/24	4/30/24
◇ Draft recommendation		5/8/24
◇ Final recommendation		6/12/24
▼ FY 2026 Funding (0%)	3/1/25	6/11/25
0% Develop funding recommendation	3/1/25	4/30/25
◇ Draft recommendation		5/14/25
◇ Final recommendation		6/11/25



TO: HSCRC Commissioners
FROM: HSCRC Staff
DATE: February 14, 2024
RE: Hearing and Meeting Schedule

Joshua Sharfstein, MD
Chairman

Joseph Antos, PhD
Vice-Chairman

James N. Elliott, MD

Ricardo R. Johnson

Maulik Joshi, DrPH

Adam Kane, Esq

Nicki McCann, JD

March 13, 2024 To be determined - GoTo Webinar

April 10, 2024 To be determined - GoTo Webinar

The Agenda for the Executive and Public Sessions will be available for your review on the Wednesday before the Commission meeting on the Commission's website at <http://hscrc.maryland.gov/Pages/commission-meetings.aspx>.

Post-meeting documents will be available on the Commission's website following the Commission meeting.

Jonathan Kromm, PhD
Executive Director

William Henderson
Director
Medical Economics & Data Analytics

Allan Pack
Director
Population-Based Methodologies

Gerard J. Schmith
Director
Revenue & Regulation Compliance

Claudine Williams
Director
Healthcare Data Management & Integrity